var data={"title":"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Molecularly targeted agents","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Molecularly targeted agents</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/contributors\" class=\"contributor contributor_credentials\">Jaime R Merchan, MD, MMSc</a></dd><dd><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/contributors\" class=\"contributor contributor_credentials\">Kenar D Jhaveri, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/contributors\" class=\"contributor contributor_credentials\">Reed E Drews, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/contributors\" class=\"contributor contributor_credentials\">Jeffrey S Berns, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/contributors\" class=\"contributor contributor_credentials\">Diane MF Savarese, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/contributors\" class=\"contributor contributor_credentials\">Albert Q Lam, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Oct 31, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H3519476740\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The development of novel anticancer therapies over the past two decades has improved patient survival rates compared with conventional chemotherapy. Several of these agents take advantage of molecular abnormalities that have been detected in certain types of cancer and are collectively referred to as molecularly targeted agents. Many of these drugs, however, have been associated with significant kidney complications, ranging from electrolyte disorders to acute kidney injury requiring dialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/1-3\" class=\"abstract_t\">1-3</a>]. </p><p>This topic review will cover renal toxicities seen with several classes of molecularly targeted and biologic agents, preventive strategies, and recommended dose modifications in patients with renal insufficiency. Nephrotoxicity and renal dose modification for conventional chemotherapeutic drugs, immune-mediated renal toxicity associated with checkpoint inhibitor immunotherapy (ie, <a href=\"topic.htm?path=ipilimumab-drug-information\" class=\"drug drug_general\">ipilimumab</a>, <a href=\"topic.htm?path=pembrolizumab-drug-information\" class=\"drug drug_general\">pembrolizumab</a>, <a href=\"topic.htm?path=nivolumab-drug-information\" class=\"drug drug_general\">nivolumab</a>), and renal toxicity associated with drugs that target the vascular endothelial growth factor (VEGF) pathway are discussed elsewhere. An overview of renal diseases associated with various cancers (including paraneoplastic syndromes), and the renal complications of tumor lysis syndrome and hematopoietic cell transplantation are also discussed separately. (See <a href=\"topic.htm?path=chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents\" class=\"medical medical_review\">&quot;Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents&quot;</a> and <a href=\"topic.htm?path=toxicities-associated-with-checkpoint-inhibitor-immunotherapy#H645724\" class=\"medical medical_review\">&quot;Toxicities associated with checkpoint inhibitor immunotherapy&quot;, section on 'Kidney'</a> and <a href=\"topic.htm?path=toxicity-of-molecularly-targeted-antiangiogenic-agents-non-cardiovascular-effects#H1651225341\" class=\"medical medical_review\">&quot;Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects&quot;, section on 'Proteinuria/nephrotic syndrome'</a> and <a href=\"topic.htm?path=overview-of-kidney-disease-in-the-cancer-patient\" class=\"medical medical_review\">&quot;Overview of kidney disease in the cancer patient&quot;</a> and <a href=\"topic.htm?path=tumor-lysis-syndrome-definition-pathogenesis-clinical-manifestations-etiology-and-risk-factors\" class=\"medical medical_review\">&quot;Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors&quot;</a> and <a href=\"topic.htm?path=kidney-disease-following-hematopoietic-cell-transplantation\" class=\"medical medical_review\">&quot;Kidney disease following hematopoietic cell transplantation&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1136913344\"><span class=\"h1\">ALK INHIBITORS</span></p><p class=\"headingAnchor\" id=\"H2194952856\"><span class=\"h2\">Crizotinib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=crizotinib-drug-information\" class=\"drug drug_general\">Crizotinib</a> is a kinase inhibitor that is approved for treatment of advanced anaplastic lymphoma kinase (ALK) fusion gene positive non-small cell lung cancer. (See <a href=\"topic.htm?path=anaplastic-lymphoma-kinase-alk-fusion-oncogene-positive-non-small-cell-lung-cancer#H11\" class=\"medical medical_review\">&quot;Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer&quot;, section on 'Crizotinib'</a>.)</p><p>Drug-induced reductions in glomerular filtration rate (GFR) are reported in patients treated with <a href=\"topic.htm?path=crizotinib-drug-information\" class=\"drug drug_general\">crizotinib</a>, mostly during the first two weeks of therapy [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/4\" class=\"abstract_t\">4</a>]. However, the early onset, small size of the change (24 percent), minimal cumulative effect, and rapid reversibility after treatment discontinuation all suggest that this is not a direct nephrotoxic effect of the drug. Nevertheless, increased vigilance with regard to concomitant use of renally cleared or nephrotoxic agents is warranted in patients receiving crizotinib. Some have suggested that the acute effects on creatinine clearance (CrCl) reflect an effect of the drug on creatinine excretion rather than a true reduction in GFR [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/5\" class=\"abstract_t\">5</a>]. If crizotinib-associated changes in creatinine-based assessments of kidney function suggest the need for dose modification of either crizotinib or concomitant medications that are renally excreted, direct measurement of GFR using external filtration markers (eg, iothalamate or <a href=\"topic.htm?path=iohexol-drug-information\" class=\"drug drug_general\">iohexol</a> clearance) may be needed. This test is available in some clinical centers, and it requires an intramuscular or intravenous injection of the marker followed by serial sampling of blood and urine. (See <a href=\"topic.htm?path=assessment-of-kidney-function#H5\" class=\"medical medical_review\">&quot;Assessment of kidney function&quot;, section on 'Measurement of GFR'</a>.)</p><p>In addition, the development of complex renal cysts (3 percent) has been described in patients treated with <a href=\"topic.htm?path=crizotinib-drug-information\" class=\"drug drug_general\">crizotinib</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/6-8\" class=\"abstract_t\">6-8</a>]. Both the formation of new cysts and progression of preexisting renal cysts can occur. Cyst development appears to be reversible upon discontinuation of the drug, and spontaneous cyst regression with continuous crizotinib treatment has also been reported [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/7\" class=\"abstract_t\">7</a>].&nbsp;The mechanism by which crizotinib induces cyst formation <span class=\"nowrap\">and/or</span> growth is unknown.</p><p>Hyponatremia and hypokalemia have also been reported with <a href=\"topic.htm?path=crizotinib-drug-information\" class=\"drug drug_general\">crizotinib</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/3,9\" class=\"abstract_t\">3,9</a>].</p><p><a href=\"topic.htm?path=crizotinib-drug-information\" class=\"drug drug_general\">Crizotinib</a> is 22 percent excreted in urine [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/10\" class=\"abstract_t\">10</a>], and drug exposure is increased in individuals with severe (but not mild to moderate) renal impairment [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/11\" class=\"abstract_t\">11</a>]. The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a51b0de-47d6-455e-a94c-d2c737b04ff7&amp;token=nApojWb4yGBhIq95pNMil2RPLnPwP26redsFENsqbtgMF67fp9SFu3Swfh6V7AJhHOKZM+qPnNaa9Rdj0T6/ys9lGsrhJ98eUDmGG0DNBw3LN66ryBkIk7F6QuWw8KkE&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">United States prescribing information</a> for crizotinib and <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">guidelines from Cancer Care Ontario</a> recommend a reduction in the starting dose to 250 mg once (rather than twice) daily in patients with CrCl &lt;30 <span class=\"nowrap\">mL/min</span> not requiring dialysis. There are no data in patients undergoing dialysis.</p><p class=\"headingAnchor\" id=\"H450284326\"><span class=\"h2\">Other ALK inhibitors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Three other ALK inhibitors are available: <a href=\"topic.htm?path=ceritinib-drug-information\" class=\"drug drug_general\">ceritinib</a>, <a href=\"topic.htm?path=alectinib-drug-information\" class=\"drug drug_general\">alectinib</a>, and <a href=\"topic.htm?path=brigatinib-drug-information\" class=\"drug drug_general\">brigatinib</a>. Clinically significant renal toxicity is not reported for these drugs, although with alectinib, increases in creatinine have been seen in 11 to 28 percent of treated patients [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/12,13\" class=\"abstract_t\">12,13</a>]. </p><p>All three drugs have minimal renal clearance. Dose adjustment for preexisting renal disease is not recommended for any of these drugs in patients with mild to moderate renal insufficiency [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/12\" class=\"abstract_t\">12</a>]. The safety of these drugs in patients with severe renal impairment or end-stage renal disease has not been specifically studied.</p><p class=\"headingAnchor\" id=\"H1461924889\"><span class=\"h1\">BCL-2 INHIBITORS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although many targeted treatments used for treatment of hematologic malignancies are associated with tumor lysis syndrome (eg, <a href=\"topic.htm?path=obinutuzumab-drug-information\" class=\"drug drug_general\">obinutuzumab</a>, <a href=\"topic.htm?path=ofatumumab-drug-information\" class=\"drug drug_general\">ofatumumab</a>), the B cell lymphoma-2 (BCL-2) inhibitor <a href=\"topic.htm?path=venetoclax-drug-information\" class=\"drug drug_general\">venetoclax</a>, which is used in the treatment of refractory chronic lymphocytic leukemia, is associated with a particularly high incidence of tumor lysis syndrome, which can cause acute kidney injury and severe electrolyte abnormalities. A gradual, stepwise dose-escalation strategy has been introduced in an effort to reduce this risk. (See <a href=\"topic.htm?path=tumor-lysis-syndrome-definition-pathogenesis-clinical-manifestations-etiology-and-risk-factors#H10\" class=\"medical medical_review\">&quot;Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors&quot;, section on 'Hematologic malignancies'</a> and <a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-chronic-lymphocytic-leukemia#H1794867576\" class=\"medical medical_review\">&quot;Treatment of relapsed or refractory chronic lymphocytic leukemia&quot;, section on 'Venetoclax'</a>.) </p><p class=\"headingAnchor\" id=\"H344532474\"><span class=\"h1\">BCR-ABL1 AND KIT INHIBITORS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are several small molecule inhibitors of BCR-ABL1, a tyrosine kinase that is the constitutively activated gene product of the Philadelphia chromosome in chronic myelogenous leukemia (CML); some also inhibit the tyrosine kinase receptor KIT (CD117) and platelet-derived growth factor (PDGFR), which are constitutively activated in gastrointestinal stromal tumors (GIST). </p><p class=\"headingAnchor\" id=\"H1044248852\"><span class=\"h2\">Bosutinib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=bosutinib-drug-information\" class=\"drug drug_general\">Bosutinib</a> is a dual tyrosine kinase inhibitor (TKI) that targets both the ABL and SRC pathways; it does not target KIT or PDGFR. It is approved for treatment of refractory CML. (See <a href=\"topic.htm?path=treatment-of-chronic-myeloid-leukemia-in-chronic-phase-after-failure-of-initial-therapy#H1349640\" class=\"medical medical_review\">&quot;Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy&quot;, section on 'Bosutinib'</a>.)</p><p>Although there are no published cases of acute kidney injury, hypophosphatemia and an apparently reversible decline in glomerular filtration rate (GFR) have been reported during long-term therapy with <a href=\"topic.htm?path=bosutinib-drug-information\" class=\"drug drug_general\">bosutinib</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/14\" class=\"abstract_t\">14</a>].<sup> </sup>The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adc84ad5-a04d-4fee-9ba8-91f7abd928e3&amp;token=JZFw8TX5j7KOR96LnDdj76Idcu/6xOJh8MKlLPQUDM5KAobnGXAUjyWfLW0Z/wJjQNYAGbP+GiATsH1RJfr2qFvyO0vKzxZz7kVMJg/BuwBciJ5Q59XuBzEYxyIgrU4i&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">United States prescribing information</a> for bosutinib recommends monitoring patients for renal function at baseline and during therapy.</p><p>The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adc84ad5-a04d-4fee-9ba8-91f7abd928e3&amp;token=JZFw8TX5j7KOR96LnDdj76Idcu/6xOJh8MKlLPQUDM5KAobnGXAUjyWfLW0Z/wJjQNYAGbP+GiATsH1RJfr2qFvyO0vKzxZz7kVMJg/BuwBciJ5Q59XuBzEYxyIgrU4i&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">United States prescribing information</a> also describes a dedicated renal impairment trial of single-dose <a href=\"topic.htm?path=bosutinib-drug-information\" class=\"drug drug_general\">bosutinib</a> in 26 patients, in whom there was a 35 and 60 percent increase in drug exposure for patients with moderate and severe preexisting renal impairment, respectively. As a result, a lower starting dose for patients with severe (creatinine clearance [CrCl] &lt;30 <span class=\"nowrap\">mL/min)</span> or moderate (CrCl 30 to 50 <span class=\"nowrap\">mL/min)</span> preexisting renal impairment is recommended. Dose reduction is also recommended for treatment-emergent renal impairment. Similar <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">guidelines</a> are available from Cancer Care Ontario.</p><p class=\"headingAnchor\" id=\"H1767880974\"><span class=\"h2\">Dasatinib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=dasatinib-drug-information\" class=\"drug drug_general\">Dasatinib</a> is a second-generation TKI used mainly in patients with imatinib-resistant CML. It has effects on BCR-ABL1 as well as PDGFR and KIT. (See <a href=\"topic.htm?path=treatment-of-chronic-myeloid-leukemia-in-chronic-phase-after-failure-of-initial-therapy#H7\" class=\"medical medical_review\">&quot;Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy&quot;, section on 'Dasatinib'</a>.)</p><p>Rare cases of acute kidney injury have been reported with the use of this agent [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/15-21\" class=\"abstract_t\">15-21</a>], including one patient who developed rhabdomyolysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/19\" class=\"abstract_t\">19</a>] and another with thrombotic thrombocytopenic purpura [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/18\" class=\"abstract_t\">18</a>]. In addition, there have been reports of proteinuria and nephrotic syndrome occurring in patients treated with <a href=\"topic.htm?path=dasatinib-drug-information\" class=\"drug drug_general\">dasatinib</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/20,21\" class=\"abstract_t\">20,21</a>]; in all cases, proteinuria resolved upon discontinuation of the drug or switching to <a href=\"topic.htm?path=imatinib-drug-information\" class=\"drug drug_general\">imatinib</a>. Of the TKIs that target the BCR-ABL pathway, dasatinib is the only agent associated with development of proteinuria.</p><p>Less than 4 percent of <a href=\"topic.htm?path=dasatinib-drug-information\" class=\"drug drug_general\">dasatinib</a> and its metabolites are renally excreted, and neither the <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4764f37b-c9e6-4ede-bcc2-8a03b7c521df&amp;token=E4aUUCfN4bBsZGkJzIZv/LOip1UCGCKugsPRwpuHF7BvkHwZr5oTE2kWz5nNX2hL3sj+hQVc6F8lRxqhUditx+ZLjt/b540xV8vedXFmH52SUXItQjucZ6MjV2LIkGsH&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">United States prescribing information</a> for dasatinib nor <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">guidelines from Cancer Care Ontario</a> indicate a need for dose adjustment in patients with preexisting renal impairment.</p><p class=\"headingAnchor\" id=\"H2722690434\"><span class=\"h2\">Imatinib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=imatinib-drug-information\" class=\"drug drug_general\">Imatinib</a> is a small molecule first-generation TKI that targets BCR-ABL1 and KIT; the drug is commonly used for treatment of both CML and GIST. (See <a href=\"topic.htm?path=clinical-use-of-tyrosine-kinase-inhibitors-for-chronic-myeloid-leukemia\" class=\"medical medical_review\">&quot;Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia&quot;</a> and <a href=\"topic.htm?path=tyrosine-kinase-inhibitor-therapy-for-advanced-gastrointestinal-stromal-tumors\" class=\"medical medical_review\">&quot;Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors&quot;</a>.)</p><p>Acute and chronic kidney injury have been described in patients treated with extended-duration <a href=\"topic.htm?path=imatinib-drug-information\" class=\"drug drug_general\">imatinib</a> for CML [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/14,22-25\" class=\"abstract_t\">14,22-25</a>]; in one report, the mean decrease in estimated GFR was 2.77 <span class=\"nowrap\">mL/min/1</span>.73 m<sup>2</sup> per year [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/22\" class=\"abstract_t\">22</a>]. Leukemic infiltration into the kidney should always be considered in the differential diagnosis when a patient with CML presents with renal impairment, regardless of the clinical stage, as the renal failure may respond to chemotherapy [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/26\" class=\"abstract_t\">26</a>]. In one study of patients with CML, acute kidney injury and chronic kidney disease occurred in 7 and 12 percent of patients, respectively [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/22\" class=\"abstract_t\">22</a>]. Potential mechanisms of injury include tumor lysis syndrome, acute tubular injury, and rhabdomyolysis; inhibition of tubular secretion of creatinine may also be a contributing factor to an observed rise in serum creatinine [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/23,24,27-31\" class=\"abstract_t\">23,24,27-31</a>].&nbsp;Renal injury appears to be dose dependent, as higher doses have been associated with a higher incidence of tubular damage [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/30\" class=\"abstract_t\">30</a>]. </p><p>Hypophosphatemia can occur in patients treated with <a href=\"topic.htm?path=imatinib-drug-information\" class=\"drug drug_general\">imatinib</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/32,33\" class=\"abstract_t\">32,33</a>]. In one case series, hypophosphatemia was associated with low serum total calcium and 25-hydroxyvitamin D levels,&nbsp;with an incidence close to 10 percent [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/32\" class=\"abstract_t\">32</a>]. The mechanism underlying hypophosphatemia is unclear, but it may be related to the inhibition of renal tubular reabsorption of phosphorus.</p><p>There is a single case report of the syndrome of inappropriate antidiuretic hormone secretion (SIADH) from high-dose <a href=\"topic.htm?path=imatinib-drug-information\" class=\"drug drug_general\">imatinib</a> in the literature. (See <a href=\"topic.htm?path=pathophysiology-and-etiology-of-the-syndrome-of-inappropriate-antidiuretic-hormone-secretion-siadh\" class=\"medical medical_review\">&quot;Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)&quot;</a>.)</p><p>The <a href=\"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=imatinib&pagesize=20&page=1&amp;token=/W0QeNH+Uuy8M26sajYYpv8IBwzVuFE/73CkRwETcWqW+n7Tw+AGw6o2JrWX33U1w9rVIUi7/g/fRfI4GNZ9aHDf8Uz6hY2KZ8nFBfi/PTSXlkvfqljGW/Tg+a8HnlGN&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">United States prescribing information</a> for <a href=\"topic.htm?path=imatinib-drug-information\" class=\"drug drug_general\">imatinib</a> recommends modification of the initial dose for patients with mild to moderate renal dysfunction (CrCl &lt;39 <span class=\"nowrap\">mL/min)</span> because of reduced drug clearance. Owing to the lack of data, patients with severe dysfunction (CrCl &lt;20 <span class=\"nowrap\">mL/min)</span> should be approached cautiously; limited data suggest a dose of 100 mg daily is tolerated in such patients [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/34\" class=\"abstract_t\">34</a>]. <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">Cancer Care Ontario guidelines</a> recommend caution in patients with mild to moderate preexisting renal insufficiency and that the drug be discontinued for CrCl &lt;20 <span class=\"nowrap\">mL/min</span>. Imatinib can be safely administered to patients on hemodialysis, although experience is limited [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/35-37\" class=\"abstract_t\">35-37</a>].</p><p>Another alternative to dose reduction for patients who develop chronic kidney disease during treatment with a first-generation TKI such as <a href=\"topic.htm?path=imatinib-drug-information\" class=\"drug drug_general\">imatinib</a> is substitution of a second-generation agent (<a href=\"topic.htm?path=dasatinib-drug-information\" class=\"drug drug_general\">dasatinib</a>, <a href=\"topic.htm?path=nilotinib-drug-information\" class=\"drug drug_general\">nilotinib</a>), which has a lower risk of kidney injury during therapy [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/38\" class=\"abstract_t\">38</a>].</p><p class=\"headingAnchor\" id=\"H116270820\"><span class=\"h2\">Other agents</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Renal dysfunction has not been reported with <a href=\"topic.htm?path=nilotinib-drug-information\" class=\"drug drug_general\">nilotinib</a>, and there are no recommendations for dose reduction for preexisting renal dysfunction. On the other hand, the molecular targets of <a href=\"topic.htm?path=ponatinib-drug-information\" class=\"drug drug_general\">ponatinib</a>, a multitargeted TKI, include the vascular endothelial growth factor (VEGF) receptor, and proteinuria is a class effect of VEGF inhibitors. (See <a href=\"#H1084264406\" class=\"local\">'VEGF pathway inhibitors'</a> below.)</p><p class=\"headingAnchor\" id=\"H1514347373\"><span class=\"h1\">BRAF AND MEK INHIBITORS</span></p><p class=\"headingAnchor\" id=\"H1635907823\"><span class=\"h2\">Vemurafenib and dabrafenib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=vemurafenib-drug-information\" class=\"drug drug_general\">Vemurafenib</a> and <a href=\"topic.htm?path=dabrafenib-drug-information\" class=\"drug drug_general\">dabrafenib</a> are potent inhibitors of the kinase domain in the mutant <em>BRAF </em>gene; they are both approved for the treatment of patients with advanced melanoma whose tumors contain a <em>BRAF</em> V600E mutation. A decrease in creatinine clearance (CrCl) has been reported in patients treated with vemurafenib, generally occurring in the first two months of therapy, which appears to be caused, at least in part, by inhibition of tubular creatinine secretion [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/39\" class=\"abstract_t\">39</a>]. This effect is generally reversible when vemurafenib is discontinued. (See <a href=\"topic.htm?path=molecularly-targeted-therapy-for-metastatic-melanoma#H1230469541\" class=\"medical medical_review\">&quot;Molecularly targeted therapy for metastatic melanoma&quot;, section on 'Vemurafenib'</a>.)</p><p>Acute kidney injury [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/40-44\" class=\"abstract_t\">40-44</a>] and one case of Fanconi syndrome have also been reported with <a href=\"topic.htm?path=vemurafenib-drug-information\" class=\"drug drug_general\">vemurafenib</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/40-42,45\" class=\"abstract_t\">40-42,45</a>]. The precise mechanism of renal injury is unclear, but kidney biopsies, when performed, have shown evidence of acute tubular damage and interstitial fibrosis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/43,44\" class=\"abstract_t\">43,44</a>]. Renal failure reported in association with vemurafenib is more common in men [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/43,44\" class=\"abstract_t\">43,44</a>]. Acute kidney injury can also occur with <a href=\"topic.htm?path=dabrafenib-drug-information\" class=\"drug drug_general\">dabrafenib</a>, although the incidence appears to be less than that with vemurafenib [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/43\" class=\"abstract_t\">43</a>].</p><p>The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38eea320-7e0c-485a-bc30-98c3c45e2763&amp;token=MmTbEIAriKvbyecUz/lxOtzY49RQlXqPw72+9jFCQlUCqzrWhXfnLW3SL3RDrBgIpnE9VBlbVxNd9w7mlx8OsScAUe+B3+LxHo6ywp6BHnJH/THfCnSDJ0c4C1Gy68BP&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">United States prescribing information</a> for <a href=\"topic.htm?path=vemurafenib-drug-information\" class=\"drug drug_general\">vemurafenib</a> and the <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=803beaaa-33f9-48cc-9a95-c2e887e095b4&amp;token=yRohpZ+tHvAM5xXEuFv+2VZvI1QLFgYtAhGvijm3z7fHmP0IDoJffm7m2KFq24FvNQhvDFh7bcMd9lYQGXPiaTaPrLycv8uqmKFxLeBWCR2Q/l3ldcLqaA/7U0djhVtq&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">United States prescribing information</a> for <a href=\"topic.htm?path=dabrafenib-drug-information\" class=\"drug drug_general\">dabrafenib</a> do not provide any dose adjustments for patients with mild to moderate renal impairment based upon the results of population pharmacokinetic testing [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/46,47\" class=\"abstract_t\">46,47</a>]. There are insufficient data to inform dosing of either drug in patients with severe renal impairment or on dialysis. <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">Guidelines from Cancer Care Ontario</a> also state that the appropriate dose has not been established in severe renal impairment, including dialysis. However, limited clinical experience suggests that it is feasible to administer vemurafenib, as well as dabrafenib in combination with <a href=\"topic.htm?path=trametinib-drug-information\" class=\"drug drug_general\">trametinib</a>, to patients with end-stage renal disease undergoing hemodialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/48,49\" class=\"abstract_t\">48,49</a>].</p><p class=\"headingAnchor\" id=\"H3704499901\"><span class=\"h2\">Trametinib and cobimetinib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=trametinib-drug-information\" class=\"drug drug_general\">Trametinib</a> and <a href=\"topic.htm?path=cobimetinib-drug-information\" class=\"drug drug_general\">cobimetinib</a> are potent and highly specific inhibitors of the mitogen-activated extracellular kinases 1 and 2 <span class=\"nowrap\">(MEK1/MEK2)</span>. They are both used for the treatment of advanced melanoma. (See <a href=\"topic.htm?path=molecularly-targeted-therapy-for-metastatic-melanoma#H100473006\" class=\"medical medical_review\">&quot;Molecularly targeted therapy for metastatic melanoma&quot;, section on 'MEK inhibition'</a>.) </p><p>There have been no published reports of nephrotoxicity associated with <a href=\"topic.htm?path=trametinib-drug-information\" class=\"drug drug_general\">trametinib</a> monotherapy, although renal insufficiency, hyponatremia, and rare cases of glomerulonephritis have been described in patients treated with the combination of BRAF and MEK inhibitors [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/50-52\" class=\"abstract_t\">50-52</a>]. Monotherapy with MEK inhibitors can lead to hypertension [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/50,53\" class=\"abstract_t\">50,53</a>].</p><p>Renal excretion of both drugs is low and unlikely to affect drug exposure [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/54,55\" class=\"abstract_t\">54,55</a>]. The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1&amp;token=T68o8mlcliPDZY2b7XwmuI3hgwW+BDlcns/QinTihLzYPVpelj5TbnxFYjhpc58OasY32O7M2vKkBQGe9tZnBXpy5CS5VmwNXOVp+SuVwNIA5g9RT711PrJiE57tVej5&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">United States prescribing information</a> for <a href=\"topic.htm?path=trametinib-drug-information\" class=\"drug drug_general\">trametinib</a> does not recommend dose adjustment for patients with mild to moderate renal impairment; a recommended dose has not been established for patients with severe renal impairment or those on dialysis. <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c387579e-cee0-4334-bd1e-73f93ac1bde6&amp;token=ZmpD6p9oKlUR4zH1zocX47UoxpCj5bbQOe6iMEIIS8fQ6w0+wR35RsVXZmUo2Xqo1f+tIs+E1jxCtOrkZ5irh8PZ6Bt8gubDEBBkB9A1tLKtZyBkBCJwLYPm7nR0M8NA&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">United States prescribing information</a> for <a href=\"topic.htm?path=cobimetinib-drug-information\" class=\"drug drug_general\">cobimetinib</a> is similarly worded. Similar <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">guidelines</a> are also available for trametinib from Cancer Care Ontario. However, as noted above, limited clinical experience suggests that it is feasible to administer trametinib in combination with <a href=\"topic.htm?path=dabrafenib-drug-information\" class=\"drug drug_general\">dabrafenib</a> to patients with end-stage renal disease undergoing hemodialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/48\" class=\"abstract_t\">48</a>].</p><p class=\"headingAnchor\" id=\"H1535999760\"><span class=\"h1\">EGFR PATHWAY INHIBITORS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Inhibitors of the epidermal growth factor receptor (EGFR) pathway include small molecule tyrosine kinase inhibitors (<a href=\"topic.htm?path=afatinib-drug-information\" class=\"drug drug_general\">afatinib</a>, <a href=\"topic.htm?path=erlotinib-drug-information\" class=\"drug drug_general\">erlotinib</a>, and <a href=\"topic.htm?path=gefitinib-drug-information\" class=\"drug drug_general\">gefitinib</a>) and monoclonal antibodies targeting the EGFR (<a href=\"topic.htm?path=cetuximab-drug-information\" class=\"drug drug_general\">cetuximab</a>, <a href=\"topic.htm?path=panitumumab-drug-information\" class=\"drug drug_general\">panitumumab</a>, and <a href=\"topic.htm?path=necitumumab-drug-information\" class=\"drug drug_general\">necitumumab</a>).</p><p class=\"headingAnchor\" id=\"H2372328215\"><span class=\"h2\">Anti-EGFR monoclonal antibodies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Monoclonal antibodies targeting the EGFR (<a href=\"topic.htm?path=cetuximab-drug-information\" class=\"drug drug_general\">cetuximab</a>, <a href=\"topic.htm?path=panitumumab-drug-information\" class=\"drug drug_general\">panitumumab</a>, and <a href=\"topic.htm?path=necitumumab-drug-information\" class=\"drug drug_general\">necitumumab</a>) are all associated with the progressive development of hypomagnesemia due to renal magnesium wasting [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/56-61\" class=\"abstract_t\">56-61</a>]. The mechanism for this has been attributed to inhibition of EGFR signaling at the distal convoluted tubule, which under normal physiologic conditions, plays an important role in regulating transepithelial magnesium transport. (See <a href=\"topic.htm?path=regulation-of-magnesium-balance#H5\" class=\"medical medical_review\">&quot;Regulation of magnesium balance&quot;, section on 'Distal reabsorption'</a>.)</p><p>The frequency of this complication with <a href=\"topic.htm?path=cetuximab-drug-information\" class=\"drug drug_general\">cetuximab</a> was illustrated in a meta-analysis of 19 clinical reports totaling 3081 patients assigned to cetuximab-based treatment [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/62\" class=\"abstract_t\">62</a>]. Thirty-seven percent of patients developed hypomagnesemia of any grade during therapy; the incidence of grade 3 or 4 hypomagnesemia (&lt;0.9 <span class=\"nowrap\">mg/dL)</span> was 5.6 percent. Whether the severity of hypomagnesemia represents a surrogate marker of oncologic outcomes in patients treated with cetuximab for advanced colorectal cancer (as is the development of an acneiform rash) is unclear; the data are conflicting [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/63-65\" class=\"abstract_t\">63-65</a>]. (See <a href=\"topic.htm?path=acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors#H31702946\" class=\"medical medical_review\">&quot;Acneiform eruption secondary to epidermal growth factor receptor (EGFR) inhibitors&quot;, section on 'Relationship between rash and survival'</a>.)</p><p>Hypomagnesemia resolves after treatment is discontinued. Hypomagnesemia may lead to secondary hypocalcemia, and periodic monitoring of serum magnesium and calcium levels is warranted during therapy and for eight weeks after treatment discontinuation. (See <a href=\"topic.htm?path=clinical-manifestations-of-magnesium-depletion\" class=\"medical medical_review\">&quot;Clinical manifestations of magnesium depletion&quot;</a> and <a href=\"topic.htm?path=regulation-of-magnesium-balance\" class=\"medical medical_review\">&quot;Regulation of magnesium balance&quot;</a> and <a href=\"topic.htm?path=systemic-chemotherapy-for-metastatic-colorectal-cancer-completed-clinical-trials\" class=\"medical medical_review\">&quot;Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials&quot;</a>.)</p><p><a href=\"topic.htm?path=cetuximab-drug-information\" class=\"drug drug_general\">Cetuximab</a> also causes hypokalemia in approximately 8 percent of patients [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/66\" class=\"abstract_t\">66</a>]. The exact mechanism underlying this complication is not established; magnesium deficiency may contribute. Thus, periodic monitoring of serum potassium is warranted during therapy with cetuximab. (See <a href=\"topic.htm?path=causes-of-hypokalemia-in-adults\" class=\"medical medical_review\">&quot;Causes of hypokalemia in adults&quot;</a>.)</p><p>In addition, other renal toxicities have been reported with <a href=\"topic.htm?path=cetuximab-drug-information\" class=\"drug drug_general\">cetuximab</a>, including acute kidney injury [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/3,67\" class=\"abstract_t\">3,67</a>], one case report of diffuse proliferative glomerulonephritis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/68\" class=\"abstract_t\">68</a>], and another case report of nephrotic syndrome [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/69\" class=\"abstract_t\">69</a>]. The cause of acute kidney injury is not clear. EGFR, which is&nbsp;mainly expressed in the distal and&nbsp;collecting tubules, is involved in maintaining tubular integrity, and activation of EGFR leads to growth and generation of tubular epithelial cells after acute tubular injury. In patients prone to experiencing renal injury, treatment with anti-EGFR agents might be a &quot;second hit&quot; for the development of acute kidney injury.</p><p>Hyponatremia has also been described in patients treated with <a href=\"topic.htm?path=cetuximab-drug-information\" class=\"drug drug_general\">cetuximab</a>. In a systematic review and meta-analysis of 13 phase III studies including 6670 patients treated with eight targeted agents, all-grade hyponatremia occurred most commonly in patients treated with the combination of brivanib and cetuximab (63.4 percent) [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/70\" class=\"abstract_t\">70</a>]. Patients treated with cetuximab had the highest incidence of high-grade hyponatremia (34.8 percent).</p><p>Renal function has no influence on the exposure to <a href=\"topic.htm?path=cetuximab-drug-information\" class=\"drug drug_general\">cetuximab</a>, <a href=\"topic.htm?path=panitumumab-drug-information\" class=\"drug drug_general\">panitumumab</a>, or <a href=\"topic.htm?path=necitumumab-drug-information\" class=\"drug drug_general\">necitumumab</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/71-76\" class=\"abstract_t\">71-76</a>]. Neither the United States prescribing information nor <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">guidelines from Cancer Care Ontario</a> provide dose modification guidelines for cetuximab or panitumumab in patients with preexisting renal impairment (including those on dialysis). The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89bcf553-669a-40b0-a9d7-67a5c1d2f591&amp;token=UWpQBtFwkidC490jYWCz0q+nTS7Ka6+pfG1nyRSLQeHRGua4txHXhqttcBKua/rAyoxDILPhcQ31uB1/ZPk66hEBzkWHyB7axjOnNgIOpAk6p58tLJDhyXZoJiv1Dl6d&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">United States prescribing information</a> for necitumumab states that no formal studies have been conducted to evaluate the effect of renal impairment on exposure to necitumumab.</p><p class=\"headingAnchor\" id=\"H1458609374\"><span class=\"h2\">EGFR tyrosine kinase inhibitors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=afatinib-drug-information\" class=\"drug drug_general\">Afatinib</a>, <a href=\"topic.htm?path=erlotinib-drug-information\" class=\"drug drug_general\">erlotinib</a>, and <a href=\"topic.htm?path=gefitinib-drug-information\" class=\"drug drug_general\">gefitinib</a> are used in the treatment of non-small cell lung cancer [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/77-80\" class=\"abstract_t\">77-80</a>]. (See <a href=\"topic.htm?path=systemic-therapy-for-advanced-non-small-cell-lung-cancer-with-an-activating-mutation-in-the-epidermal-growth-factor-receptor\" class=\"medical medical_review\">&quot;Systemic therapy for advanced non-small cell lung cancer with an activating mutation in the epidermal growth factor receptor&quot;</a>.)</p><p>Electrolyte disorders, such as hypomagnesemia, hypokalemia, and hypophosphatemia, have been reported with all three agents, although the incidence overall seems less than that with the EGFR monoclonal antibodies [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/3\" class=\"abstract_t\">3</a>]. In addition, there are case reports of nephrotic syndrome with renal biopsy findings consistent with minimal-change disease and membranous nephropathy occurring in patients treated with <a href=\"topic.htm?path=gefitinib-drug-information\" class=\"drug drug_general\">gefitinib</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/81-83\" class=\"abstract_t\">81-83</a>].</p><p>Less than 8 percent of <a href=\"topic.htm?path=gefitinib-drug-information\" class=\"drug drug_general\">gefitinib</a>, <a href=\"topic.htm?path=erlotinib-drug-information\" class=\"drug drug_general\">erlotinib</a>, and their metabolites are excreted in the urine. Although data are limited, dose modification for erlotinib and gefitinib is not required in patients with impaired renal function, including those on dialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/12,77-80\" class=\"abstract_t\">12,77-80</a>].</p><p>Moderate to severe renal impairment has a minor influence on the pharmacokinetics of <a href=\"topic.htm?path=afatinib-drug-information\" class=\"drug drug_general\">afatinib</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/84\" class=\"abstract_t\">84</a>]. Nevertheless, the <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd638e5e-8032-e7ca-0179-95e96ab5d387&amp;token=ulzhk4WJOBH8NMqpNDDLl9TSYdAmWwY4SZUzwotkLi9V5iSATebkrJeSnn9KaOFU7fZf78tQ/K2beYgLVZ8vwrHBWFIyjQ+IypLPC8OxSdDwbEnO9jrzqBoAejjAKHjt&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">United States prescribing information</a> for afatinib recommends dose modification for patients with severe renal impairment (estimated glomerular filtration rate [GFR] 15 to 29 <span class=\"nowrap\">mL/min/1</span>.73 m<sup>2</sup>). <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">Guidelines from Cancer Care Ontario</a> also support a reduced dose for creatinine clearance (CrCl) 15 to 29 <span class=\"nowrap\">mL/min</span> and that the drug be avoided with more severe renal failure or in patients undergoing dialysis. However, at least two case series support the safety of a reduced dose of afatinib (30 mg daily) in patients undergoing hemodialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/85,86\" class=\"abstract_t\">85,86</a>].</p><p class=\"headingAnchor\" id=\"H2112553951\"><span class=\"h1\">HER2 INHIBITORS</span></p><p class=\"headingAnchor\" id=\"H1640769996\"><span class=\"h2\">Trastuzumab, ado-trastuzumab emtansine, and pertuzumab</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=trastuzumab-including-biosimilars-of-trastuzumab-drug-information\" class=\"drug drug_general\">Trastuzumab</a> is a recombinant humanized monoclonal antibody that binds to the extracellular domain of human epidermal growth factor receptor 2 (HER2) and inhibits proliferation of cells that overexpress the HER2 protein. <a href=\"topic.htm?path=ado-trastuzumab-emtansine-drug-information\" class=\"drug drug_general\">Ado-trastuzumab emtansine</a> (T-DM1) is an antibody-drug conjugate consisting of trastuzumab linked to the microtubule inhibitor emtansine (DM1), a derivative of maytansine. <a href=\"topic.htm?path=pertuzumab-drug-information\" class=\"drug drug_general\">Pertuzumab</a> is a humanized monoclonal antibody that binds the extracellular dimerization domain of HER2 and prevents it from binding to itself or to other members of the epidermal growth factor receptor (EGFR) family. Pertuzumab is typically administered in combination with trastuzumab rather than as a single agent; all three drugs are used for the treatment of HER2-positive breast cancer. (See <a href=\"topic.htm?path=systemic-treatment-for-her2-positive-metastatic-breast-cancer\" class=\"medical medical_review\">&quot;Systemic treatment for HER2-positive metastatic breast cancer&quot;</a>.)</p><p>There are no published case reports of nephrotoxicity with either <a href=\"topic.htm?path=trastuzumab-including-biosimilars-of-trastuzumab-drug-information\" class=\"drug drug_general\">trastuzumab</a> or <a href=\"topic.htm?path=pertuzumab-drug-information\" class=\"drug drug_general\">pertuzumab</a>. An analysis of the US Food and Drug Administration (FDA) Adverse Event Reporting System identified a total of 360 and 100 renal adverse events for trastuzumab and pertuzumab, respectively, reported between 2011 and 2015 [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/3\" class=\"abstract_t\">3</a>]. Among the most commonly reported events were renal impairment (defined as proteinuria, acute kidney injury, elevated serum creatinine, <span class=\"nowrap\">and/or</span> nephritis), hypokalemia, hypertension, hypomagnesemia, and hyponatremia. However, it is not clear that these renal events were directly caused by the drugs as opposed to the underlying disease, concomitant medications, or prior chemotherapy given to these patients.</p><p>Rare cases of fetal nephrotoxicity associated with anhydramnios have been described with <a href=\"topic.htm?path=trastuzumab-including-biosimilars-of-trastuzumab-drug-information\" class=\"drug drug_general\">trastuzumab</a> administered during pregnancy; in three cases, there was spontaneous improvement after discontinuation of trastuzumab [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/87-89\" class=\"abstract_t\">87-89</a>]. (See <a href=\"topic.htm?path=gestational-breast-cancer-treatment#H84662677\" class=\"medical medical_review\">&quot;Gestational breast cancer: Treatment&quot;, section on 'Trastuzumab'</a>.)</p><p>Patients treated with <a href=\"topic.htm?path=ado-trastuzumab-emtansine-drug-information\" class=\"drug drug_general\">ado-trastuzumab emtansine</a> can develop hypokalemia during therapy (overall incidence approximately 10 percent of any grade, 2 to 3 percent grade 3 or 4 (<a href=\"image.htm?imageKey=HEME%2F91252\" class=\"graphic graphic_table graphicRef91252 \">table 1</a>)) [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/75,90\" class=\"abstract_t\">75,90</a>]. </p><p>Renal excretion of <a href=\"topic.htm?path=trastuzumab-including-biosimilars-of-trastuzumab-drug-information\" class=\"drug drug_general\">trastuzumab</a> is very low [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/91\" class=\"abstract_t\">91</a>]. However, among patients treated with trastuzumab, the presence of preexisting renal impairment has been associated with a higher risk of cardiotoxicity. One study found that an estimated glomerular filtration rate (GFR) of &lt;78 <span class=\"nowrap\">mL/min/1</span>.73 m<sup>2</sup> was an independent predictor for cardiotoxicity at 12 months posttreatment [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/92\" class=\"abstract_t\">92</a>]. (See <a href=\"topic.htm?path=cardiotoxicity-of-trastuzumab-and-other-her2-targeted-agents\" class=\"medical medical_review\">&quot;Cardiotoxicity of trastuzumab and other HER2-targeted agents&quot;</a>.)</p><p>Despite this finding, drug disposition does not appear to be altered in patients with renal insufficiency. <a href=\"topic.htm?path=pertuzumab-drug-information\" class=\"drug drug_general\">Pertuzumab</a> dose adjustments are not needed for mild to moderate renal impairment; elimination has not been studied in patients with severe renal impairment (&lt;30 <span class=\"nowrap\">mL/min)</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/12\" class=\"abstract_t\">12</a>]. There are no dose adjustments for patients with renal impairment, including those on dialysis, for either <a href=\"topic.htm?path=trastuzumab-including-biosimilars-of-trastuzumab-drug-information\" class=\"drug drug_general\">trastuzumab</a> in the <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=492dbdb2-077e-4064-bff3-372d6af0a7a2&amp;token=bHBiLfkvY54cMFJjpPF4CKHYAMIBn5Ip2bWy0l7As60E/Cd6xrl7WYQSeOlIIc+sJFI5uVIQvniuZhqIxR33Xifh6zr4zeFLI69H2ef1PEYlnR0C1AtgvFMQFhfT/zRm&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">United States prescribing information</a> or for pertuzumab in the <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17f85d17-ab71-4f5b-9fe3-0b8c822f69ff&amp;token=STLoTdgvUyUVXBn12Tli9xSLOfRV0+PbihUiyGTi+XCEtUWp5tzeCBmQktqx3coVe6xwAr3TO6rAPUP4FhRXSBBZmILXfOMAk6ISpEWDyV2EWJOOXbOzwWm8djidxo2O&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">United States prescribing information</a>. There are scant data in the literature about use of either drug in patients undergoing dialysis. One report noted good clinical outcomes in two patients treated with standard-dose trastuzumab while receiving dialysis; pharmacokinetic data were not available [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/93\" class=\"abstract_t\">93</a>].</p><p>There are no dose adjustments for patients with renal impairment, including those on dialysis, in the <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e&amp;token=WkhxnAo8cwII01ZPqUe9Z/0BDz/iyh9MQIp1zxRgeFhxtRFm1azMllJrQlD3AgnAl4V/l4qIarWcIcMDwSy1UNRQZeSxk7l5JyTS+WOB0AeUEvZCs/ShsE1syWdGh4q1&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">United States prescribing information</a> for <a href=\"topic.htm?path=ado-trastuzumab-emtansine-drug-information\" class=\"drug drug_general\">ado-trastuzumab emtansine</a>.</p><p class=\"headingAnchor\" id=\"H3979482629\"><span class=\"h2\">Lapatinib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=lapatinib-drug-information\" class=\"drug drug_general\">Lapatinib</a> is a dual tyrosine kinase inhibitor that interrupts both the EGFR (erbB1) and HER2 (erbB2) pathways. In a phase II trial with this agent, seven patients experienced treatment-related grade 3 toxicity, two of whom developed hyponatremia [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/94\" class=\"abstract_t\">94</a>]. An analysis of the FDA Adverse Event Reporting System identified a total of 171 renal adverse events reported between 2011 and 2015, most of which were cases of hypokalemia (61 cases) and acute kidney injury (48 cases); a few cases of hypertension, hypomagnesemia, and hyponatremia were also reported [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/3\" class=\"abstract_t\">3</a>].</p><p>The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63319b01-cad6-4d0a-c39b-938fa951a808&amp;token=n1PBkuOvZqiUmJHawz/dda1i7OP/Ta5Opch6k9lE68H6cY8a3Pypk82sPqEjdJOXJ9Y6ABpmEl1Uu+4+tOS6mQW8/hznQRzaEYqviZH+wKRlzC3ajPmeAbNJwmDlWcXr&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">United States prescribing information</a> for <a href=\"topic.htm?path=lapatinib-drug-information\" class=\"drug drug_general\">lapatinib</a> provides no dose adjustments for patients with renal impairment; however, due to the minimal renal elimination (&lt;2 percent), dose adjustments may not be necessary.</p><p class=\"headingAnchor\" id=\"H993681564\"><span class=\"h1\">MTOR INHIBITORS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The extensive experience with mechanistic (previously called mammalian) target of rapamycin (mTOR) inhibitors in solid organ transplantation as well as advances in our understanding of the role of the <span class=\"nowrap\">Akt/mTOR</span> pathway in the maintenance of podocyte viability have led to concerns about short- and long-term nephrotoxicity with these agents [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/95,96\" class=\"abstract_t\">95,96</a>]. (See <a href=\"topic.htm?path=biology-of-glomerular-podocytes#H7\" class=\"medical medical_review\">&quot;Biology of glomerular podocytes&quot;, section on 'Direct podocyte injury'</a>.) </p><p>Proteinuria and, more rarely, kidney dysfunction have been reported in patients taking mTOR inhibitors. The phenomena appear to be dose dependent and reversible with cessation of the medication. These issues are discussed in more detail elsewhere. (See <a href=\"topic.htm?path=pharmacology-of-mammalian-mechanistic-target-of-rapamycin-mtor-inhibitors#H25\" class=\"medical medical_review\">&quot;Pharmacology of mammalian (mechanistic) target of rapamycin (mTOR) inhibitors&quot;, section on 'Kidney function'</a>.)</p><p class=\"headingAnchor\" id=\"H2177291577\"><span class=\"h2\">Temsirolimus</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=temsirolimus-drug-information\" class=\"drug drug_general\">Temsirolimus</a> is a parenterally administered rapamycin analog that functions as a competitive mTOR inhibitor. (See <a href=\"topic.htm?path=antiangiogenic-and-molecularly-targeted-therapy-for-advanced-or-metastatic-clear-cell-renal-cell-carcinoma\" class=\"medical medical_review\">&quot;Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear-cell renal cell carcinoma&quot;</a>.)</p><p>There are rare case reports of temsirolimus-associated glomerulopathy and acute tubular necrosis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/97,98\" class=\"abstract_t\">97,98</a>].</p><p><a href=\"topic.htm?path=temsirolimus-drug-information\" class=\"drug drug_general\">Temsirolimus</a> is cleared mainly by the liver, with some excretion in the feces. Due to the small amount of renal excretion (less than 5 percent), dose adjustment is not needed in the setting of renal insufficiency or end-stage renal disease on hemodialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/12,99\" class=\"abstract_t\">12,99</a>]. However, one study did note a higher rate of treatment-related rash (45 versus 15 percent) and infection (27 versus 8 percent) in patients receiving mTOR inhibitors for renal cell cancer who had preexisting renal insufficiency (creatinine clearance [CrCl] &le;60 <span class=\"nowrap\">mL/min)</span> compared with those with normal renal function [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/100\" class=\"abstract_t\">100</a>]. </p><p class=\"headingAnchor\" id=\"H1084264406\"><span class=\"h1\">VEGF PATHWAY INHIBITORS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Two different approaches have been used to block the vascular endothelial growth factor (VEGF) pathway: VEGF ligand inhibitors (<a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">bevacizumab</a>, <a href=\"topic.htm?path=ramucirumab-drug-information\" class=\"drug drug_general\">ramucirumab</a>, and <a href=\"topic.htm?path=aflibercept-drug-information\" class=\"drug drug_general\">aflibercept</a>), which bind to and inhibit ligand binding to the VEGF receptor (VEGFR), thus preventing activation of the receptor, and small molecule tyrosine kinase inhibitors (TKIs; <a href=\"topic.htm?path=sunitinib-drug-information\" class=\"drug drug_general\">sunitinib</a>, <a href=\"topic.htm?path=sorafenib-drug-information\" class=\"drug drug_general\">sorafenib</a>, <a href=\"topic.htm?path=pazopanib-drug-information\" class=\"drug drug_general\">pazopanib</a>, <a href=\"topic.htm?path=ponatinib-drug-information\" class=\"drug drug_general\">ponatinib</a>, <a href=\"topic.htm?path=axitinib-drug-information\" class=\"drug drug_general\">axitinib</a>, <a href=\"topic.htm?path=cabozantinib-drug-information\" class=\"drug drug_general\">cabozantinib</a>, <a href=\"topic.htm?path=lenvatinib-drug-information\" class=\"drug drug_general\">lenvatinib</a>, <a href=\"topic.htm?path=regorafenib-drug-information\" class=\"drug drug_general\">regorafenib</a>, <a href=\"topic.htm?path=vandetanib-drug-information\" class=\"drug drug_general\">vandetanib</a>), which block the intracellular domain of the VEGFR.</p><p>Proteinuria is a class effect of all VEGF inhibitors. <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">Bevacizumab</a>, <a href=\"topic.htm?path=ramucirumab-drug-information\" class=\"drug drug_general\">ramucirumab</a>, <a href=\"topic.htm?path=aflibercept-drug-information\" class=\"drug drug_general\">aflibercept</a>, and the small molecule antiangiogenic TKIs all produce asymptomatic proteinuria, occasionally causing nephrotic syndrome. Hypertension frequently accompanies proteinuria. (See <a href=\"topic.htm?path=toxicity-of-molecularly-targeted-antiangiogenic-agents-cardiovascular-effects#H21639449\" class=\"medical medical_review\">&quot;Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects&quot;, section on 'Hypertension'</a> and <a href=\"topic.htm?path=toxicity-of-molecularly-targeted-antiangiogenic-agents-non-cardiovascular-effects#H1651225341\" class=\"medical medical_review\">&quot;Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects&quot;, section on 'Proteinuria/nephrotic syndrome'</a>.)</p><p>The exact mechanism underlying proteinuria is not known. Reports of renal biopsies among patients with proteinuria receiving VEGF-targeted agents are sparse; when reported, the most common causative agent was <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">bevacizumab</a>. Histologic findings have included thrombotic microangiography, collapsing glomerulopathy, and isolated reports of cryoglobulinemic and immune complex glomerulonephritis. The factors associated with the occurrence and severity of proteinuria are unknown. Preexisting renal disease (including higher baseline urine protein levels and hypertension) and renal cell carcinoma, as compared with other malignant diseases, may be predisposing factors. (See <a href=\"topic.htm?path=toxicity-of-molecularly-targeted-antiangiogenic-agents-non-cardiovascular-effects#H388130\" class=\"medical medical_review\">&quot;Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects&quot;, section on 'Incidence and mechanism'</a>.) </p><p>The implications of asymptomatic proteinuria from VEGF inhibitors are unknown, and it is possible that the vast majority of cases have no clinical consequences. However, proteinuria has been linked to adverse cardiovascular outcomes and progression to end-stage renal disease (ESRD) in patients with chronic kidney disease, and as such, proteinuria is identified as a target for treatment in kidney diseases in general. (See <a href=\"topic.htm?path=secondary-factors-and-progression-of-chronic-kidney-disease#H5\" class=\"medical medical_review\">&quot;Secondary factors and progression of chronic kidney disease&quot;, section on 'Proteinuria'</a>.)</p><p>The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=939b5d1f-9fb2-4499-80ef-0607aa6b114e&amp;token=MgNA0H4pFebH733Bej56O4GI5fLpgRzk7iIVh6iYv6tbmervjGc7QbFrDOuwzLyaD+QSia3ek8jf9yumdvDMmRwynXinbeXIy7CceSOGer9UHUxe6uzNAmF4t1rKoO+9&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">United States prescribing information</a> for <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">bevacizumab</a> recommends intermittent monitoring for the development of proteinuria but does not provide specific recommendations, except temporary withholding of the drug if protein excretion is &gt;2 g per 24 hours, and permanent discontinuation for nephrotic syndrome. However, this complication is uncommon, and many institutions do not routinely dipstick urine prior to each dose of bevacizumab. Baseline and periodic urinalyses are also recommended during treatment with <a href=\"topic.htm?path=pazopanib-drug-information\" class=\"drug drug_general\">pazopanib</a>, <a href=\"topic.htm?path=lenvatinib-drug-information\" class=\"drug drug_general\">lenvatinib</a>, and <a href=\"topic.htm?path=axitinib-drug-information\" class=\"drug drug_general\">axitinib</a>, with treatment interruption or discontinuation for patients who develop moderate to severe proteinuria (defined as &ge;3 g per 24 hours for pazopanib and &ge;2 g per 24 hours for lenvatinib, but undefined for axitinib). There are no guidelines for <a href=\"topic.htm?path=sorafenib-drug-information\" class=\"drug drug_general\">sorafenib</a>, <a href=\"topic.htm?path=sunitinib-drug-information\" class=\"drug drug_general\">sunitinib</a>, <a href=\"topic.htm?path=vandetanib-drug-information\" class=\"drug drug_general\">vandetanib</a>, <a href=\"topic.htm?path=ponatinib-drug-information\" class=\"drug drug_general\">ponatinib</a>, <a href=\"topic.htm?path=regorafenib-drug-information\" class=\"drug drug_general\">regorafenib</a>, or <a href=\"topic.htm?path=cabozantinib-drug-information\" class=\"drug drug_general\">cabozantinib</a>; however, good clinical practice dictates baseline and periodic assessment of proteinuria for these agents as well. (See <a href=\"topic.htm?path=toxicity-of-molecularly-targeted-antiangiogenic-agents-non-cardiovascular-effects#H1651225348\" class=\"medical medical_review\">&quot;Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects&quot;, section on 'Management'</a>.)</p><p>Less commonly, nephritic syndrome, acute kidney injury, and proliferative glomerulonephritis have been reported with <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">bevacizumab</a>; acute kidney injury and diabetes insipidus have been reported in clinical trials of <a href=\"topic.htm?path=vandetanib-drug-information\" class=\"drug drug_general\">vandetanib</a> in medullary thyroid and lung cancer, although causality has not been proven. Increases in creatinine during therapy have been reported with <a href=\"topic.htm?path=axitinib-drug-information\" class=\"drug drug_general\">axitinib</a>, <a href=\"topic.htm?path=sunitinib-drug-information\" class=\"drug drug_general\">sunitinib</a>, and <a href=\"topic.htm?path=sorafenib-drug-information\" class=\"drug drug_general\">sorafenib</a>, although renal failure is rare. (See <a href=\"topic.htm?path=toxicity-of-molecularly-targeted-antiangiogenic-agents-non-cardiovascular-effects#H388130\" class=\"medical medical_review\">&quot;Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects&quot;, section on 'Incidence and mechanism'</a>.) </p><p>Monoclonal antibodies are generally cleared by catabolism; for <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">bevacizumab</a>, <a href=\"topic.htm?path=aflibercept-drug-information\" class=\"drug drug_general\">aflibercept</a>, and <a href=\"topic.htm?path=ramucirumab-drug-information\" class=\"drug drug_general\">ramucirumab</a>, no dosing adjustment is recommended for patients with renal impairment, including those undergoing dialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/101,102\" class=\"abstract_t\">101,102</a>].</p><p>Small molecule TKIs are partly excreted by the kidneys. In general, these drugs can be safely given to patients with mild to moderate renal insufficiency, with adequate monitoring and dose adjustment as needed [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/100,103\" class=\"abstract_t\">100,103</a>]. Most of these drugs have not been studied in patients with severe renal impairment or ESRD. However, at least one report suggests that more than one-half of patients who have chronic kidney disease at the start of therapy will experience a further rise in creatinine during treatment with <a href=\"topic.htm?path=sunitinib-drug-information\" class=\"drug drug_general\">sunitinib</a> or <a href=\"topic.htm?path=sorafenib-drug-information\" class=\"drug drug_general\">sorafenib</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/103\" class=\"abstract_t\">103</a>]. Agent-specific nephrotoxicity and dose modification are discussed below.</p><p class=\"headingAnchor\" id=\"H3363773602\"><span class=\"h2\">Lenvatinib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=lenvatinib-drug-information\" class=\"drug drug_general\">Lenvatinib</a> is an orally active inhibitor of several tyrosine kinases, including RET, KIT, VEGFR, and platelet-derived growth factor receptor alpha (PDGFRA). No renal toxicities have been reported with this drug. </p><p>The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4bedd21-efde-44c6-9d9c-b48b78d7ed1e&amp;token=S4mDoP+3RrqrqzG8ruBV5MqCxTawlfE9HHdg6cfC5lS9Jp3yjpr5X/KtBeGm7SwndYHMJkkeyYJ8wil/RGRS4Q6KtAR4B1fwJ/lYEfx0qXIuD67BLRWFMTvpw36ILHwv&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">United States prescribing information</a> for <a href=\"topic.htm?path=lenvatinib-drug-information\" class=\"drug drug_general\">lenvatinib</a> does not recommend adjustment of the initial dose of this agent (24 mg once daily) in patients with mild to moderate renal impairment. In patients with severe preexisting renal impairment (creatinine clearance [CrCl] &lt;30 <span class=\"nowrap\">mL/min),</span> a reduced initial dose of 14 mg daily is recommended. A similar <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">recommendation</a> is made by Cancer Care Ontario. No studies have been conducted in patients with ESRD, and guidance is not available from either source.</p><p class=\"headingAnchor\" id=\"H1973950167\"><span class=\"h2\">Regorafenib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=regorafenib-drug-information\" class=\"drug drug_general\">Regorafenib</a> is an orally administered inhibitor of angiogenic (including VEGFR 1 to 3), stromal, and oncogenic receptor tyrosine kinases. </p><p>In addition to hypertension and the proteinuria that is seen with other antiangiogenic TKIs, <a href=\"topic.htm?path=regorafenib-drug-information\" class=\"drug drug_general\">regorafenib</a> has been associated with several electrolyte abnormalities, including hypophosphatemia, hypocalcemia, hyponatremia, and hypokalemia [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/104-106\" class=\"abstract_t\">104-106</a>]. These abnormalities are usually mild to moderate and do not require dose reductions or treatment interruptions. An analysis of the US Food and Drug Administration (FDA) Adverse Event Reporting System identified a total of 125 cases of regorafenib-associated renal adverse events between 2011 and 2015; hypertension was the most common event (57 cases), followed by renal impairment (40 cases) and hypophosphatemia (eight cases) [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/3\" class=\"abstract_t\">3</a>].</p><p>The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=824f19c9-0546-4a8a-8d8f-c4055c04f7c7&amp;token=mUp/w7nyNMfDujrAss6GEW+yf/vwb2/nuXjYYzk3hulIm2D6CGauR7xnPx1FT0JTZ+d1cF6RI9FB2CXOZZzsejDFzk06+2jRXv64zhwWHM1ySktk2fpxgUaX9NubC21W&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">United States prescribing information</a> for <a href=\"topic.htm?path=regorafenib-drug-information\" class=\"drug drug_general\">regorafenib</a> does not recommend adjustment of the initial dose for patients with CrCl &gt;15 <span class=\"nowrap\">mL/min</span>. There are no data to guide treatment in patients undergoing dialysis. Similarly, <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">guidelines from Cancer Care Ontario</a> suggest no dose adjustment for CrCl 60 to 90 <span class=\"nowrap\">mL/min</span> and close monitoring without initial dose adjustment for moderate renal impairment; no data are available in severe renal impairment or ESRD.</p><p class=\"headingAnchor\" id=\"H3855205339\"><span class=\"h2\">Sorafenib and sunitinib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=sorafenib-drug-information\" class=\"drug drug_general\">Sorafenib</a> and <a href=\"topic.htm?path=sunitinib-drug-information\" class=\"drug drug_general\">sunitinib</a> have been associated with acute and chronic interstitial nephritis in case reports [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/107-109\" class=\"abstract_t\">107-109</a>]. Sorafenib is also known to cause hypophosphatemia and hypocalcemia [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/110\" class=\"abstract_t\">110</a>]. This effect has been attributed to vitamin D malabsorption and secondary hyperparathyroidism, although the precise mechanism for this is unclear [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/111\" class=\"abstract_t\">111</a>].&nbsp;Thus, in patients taking sorafenib, vitamin D, phosphorus, and calcium levels should be routinely monitored. </p><p>The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b50667e4-5ebc-4968-a646-d605058dbef0&amp;token=/lYDOMH5elzjhbsDpVmcucqhsgDCjS5fyKsaIvmCOydvrCgshhkjt/zBoTVwfbXIjlskzoeiXoxlGC2B3WvUu8tEAgtcLnIAau0jP7ViJMnhp9hnGsWkmnNYGnb5bvRh&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">United States prescribing information</a> for <a href=\"topic.htm?path=sorafenib-drug-information\" class=\"drug drug_general\">sorafenib</a> suggests no dose adjustment for patients with mild, moderate, or severe renal impairment not undergoing dialysis. However, a phase I study indicated that the initial dose of sorafenib should be reduced to 200 mg twice daily for patients with a CrCl between 20 and 30 <span class=\"nowrap\">mL/min</span> and to 200 mg once daily for those on hemodialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/112\" class=\"abstract_t\">112</a>]. Conclusions regarding initial dose could not be reached in patients with a CrCl less than 20 <span class=\"nowrap\">mL/min</span> who were not undergoing hemodialysis. Guidelines from others, including <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a>, suggest reducing the dose by one-half for CrCl 20 to 40 <span class=\"nowrap\">mL/min</span> and avoiding the drug with worse renal function [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/37\" class=\"abstract_t\">37</a>].</p><p>Some patients undergoing dialysis may tolerate higher doses. Doses of 200 mg twice daily have been associated with a higher incidence of adverse effects in patients undergoing hemodialysis in some [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/113\" class=\"abstract_t\">113</a>], but not all [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/114\" class=\"abstract_t\">114</a>], studies. Some patients may even tolerate dose escalation to 400 mg twice daily [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/115,116\" class=\"abstract_t\">115,116</a>].</p><p>The pharmacokinetics and safety of <a href=\"topic.htm?path=sunitinib-drug-information\" class=\"drug drug_general\">sunitinib</a> have been evaluated in a small number of patients with renal insufficiency [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/103,114,116-120\" class=\"abstract_t\">103,114,116-120</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a study of 24 patients, a single dose of 50 mg of <a href=\"topic.htm?path=sunitinib-drug-information\" class=\"drug drug_general\">sunitinib</a> appeared to be well tolerated in those with severe renal impairment (CrCl &lt;30 <span class=\"nowrap\">mL/min)</span> or ESRD on hemodialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/114\" class=\"abstract_t\">114</a>]. The pharmacokinetics of sunitinib and its major metabolite (SU12662) in patients with severe renal impairment appeared similar to that in patients with normal renal function, while in patients with ESRD, plasma exposure to both sunitinib and SU12662 was actually 47 percent lower compared with patients with normal or severely impaired renal function not on dialysis.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a published case report of two patients with ESRD receiving repeated doses of <a href=\"topic.htm?path=sunitinib-drug-information\" class=\"drug drug_general\">sunitinib</a> (daily for four weeks on, two weeks off) for renal cell cancer, the pharmacokinetics of sunitinib were similar to those in patients with normal renal function [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/118\" class=\"abstract_t\">118</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Another report included 19 patients with an estimated glomerular filtration rate (GFR) &lt;30 <span class=\"nowrap\">mL/min</span> at the start of <a href=\"topic.htm?path=sunitinib-drug-information\" class=\"drug drug_general\">sunitinib</a> therapy for advanced renal cell cancer, 10 of whom were undergoing dialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/119\" class=\"abstract_t\">119</a>]. Starting doses were 25 to 50 mg daily for four of every six weeks. Treatment efficacy was comparable to that reported in patients with normal renal function. Dose reduction for toxicity was required in eight patients, but only one patient required treatment discontinuation. Similar results have been reported by others in patients with renal cell cancer undergoing hemodialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/114\" class=\"abstract_t\">114</a>].</p><p/><p>Thus, these data suggest that <a href=\"topic.htm?path=sunitinib-drug-information\" class=\"drug drug_general\">sunitinib</a> doses of 25 to 50 mg daily are well tolerated in patients with severe renal dysfunction or ESRD on hemodialysis. The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=43a4d7f8-48ae-4a63-9108-2fa8e3ea9d9c&amp;token=wuzyzCVf3vjVCXX2cvJEzCHVwt8rZXoi2q6XTh2WdW+14i2S+IDhFGUtSJx/VXMFUnUQQizAuMIwFCWcvrgVFAR+O7KkEdrX5S1hFPMqd+bYsfTPgMediTKna5TwSKSO&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">United States prescribing information</a> for sunitinib concludes that no adjustment to the starting dose is required in patients with mild, moderate, and severe renal impairment. They also note that for patients with ESRD on hemodialysis, the sunitinib exposure is actually lower and that subsequent doses may be increased gradually up to twofold based upon safety and tolerability. Similar guidance is available from others, including <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/37\" class=\"abstract_t\">37</a>].</p><p class=\"headingAnchor\" id=\"H1794327396\"><span class=\"h2\">Vandetanib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=vandetanib-drug-information\" class=\"drug drug_general\">Vandetanib</a> is an orally active inhibitor of several tyrosine kinases, including RET, VEGFR, and endothelial growth factor receptor (EGFR). As noted in the <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525&amp;token=B5pIw8Y+2+kuzyRM3V3E+Guw706VvCKsBQo/F0jOtwBgxH+VBZVcqEN0w+4v5TwA0LZGSHgc571j38NfUjc0bLSJh0/Nll3JzZtPh378DmNstyip697bnfJiPvlYM2m6&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">United States prescribing information</a> for vandetanib, increases in creatinine during therapy occur in approximately 16 percent of patients and may be severe.</p><p><a href=\"topic.htm?path=vandetanib-drug-information\" class=\"drug drug_general\">Vandetanib</a> has been associated with a number of electrolyte disturbances, such as hypocalcemia, hypomagnesemia, hypokalemia, hyponatremia, and hypercalcemia [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/121,122\" class=\"abstract_t\">121,122</a>]. Hypertension has been reported in approximately 10 to 34 percent of patients [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/121,123,124\" class=\"abstract_t\">121,123,124</a>]. An analysis of the FDA Adverse Event Reporting System identified a total of 57 renal adverse events for vandetanib reported between 2011 and 2015; the majority were renal impairment (defined as proteinuria, acute kidney injury, elevated serum creatinine, <span class=\"nowrap\">and/or</span> nephritis; 30 cases) and hypertension (21 cases), with the remainder being electrolyte disorders. However, it is not clear that these renal events were directly caused by the drug as opposed to the underlying disease, concomitant medications, or prior chemotherapy given to these patients. </p><p><a href=\"topic.htm?path=vandetanib-drug-information\" class=\"drug drug_general\">Vandetanib</a> has also been shown to have inhibitory activity on several human renal transporters, such as multidrug and toxin extrusion 1 and 2 (MATE-1 and MATE-2K), which are responsible for the clearance of multiple drugs and toxins. Inhibition of MATE-1 and MATE-2K at the apical membrane of the tubular cells might lead to decreased renal clearance and increased nephrotoxicity of other coadministered agents, such as <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/125\" class=\"abstract_t\">125</a>].</p><p><a href=\"topic.htm?path=vandetanib-drug-information\" class=\"drug drug_general\">Vandetanib</a> is partially excreted in urine, and exposure is increased in subjects with mild, moderate, and severe renal impairment [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/126\" class=\"abstract_t\">126</a>]. </p><p>The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525&amp;token=B5pIw8Y+2+kuzyRM3V3E+Guw706VvCKsBQo/F0jOtwBgxH+VBZVcqEN0w+4v5TwA0LZGSHgc571j38NfUjc0bLSJh0/Nll3JzZtPh378DmNstyip697bnfJiPvlYM2m6&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">United States prescribing information</a> for <a href=\"topic.htm?path=vandetanib-drug-information\" class=\"drug drug_general\">vandetanib</a> recommends a dose reduction from 300 to 200 mg daily for patients with moderate to severe renal insufficiency (CrCl &le;50 <span class=\"nowrap\">mL/min)</span>. Similar recommendations are available from others, including <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/37\" class=\"abstract_t\">37</a>]. </p><p class=\"headingAnchor\" id=\"H213403592\"><span class=\"h1\">OTHER TARGETED AGENTS</span></p><p class=\"headingAnchor\" id=\"H615177114\"><span class=\"h2\">Brentuximab</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=brentuximab-vedotin-drug-information\" class=\"drug drug_general\">Brentuximab vedotin</a> is an antibody-drug conjugate with a CD30-directed antibody linked to the antitubulin agent monomethyl auristatin E (MMAE). It is approved for the treatment of refractory Hodgkin lymphoma and anaplastic large cell lymphoma. (See <a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma#H2145853771\" class=\"medical medical_review\">&quot;Treatment of relapsed or refractory peripheral T cell lymphoma&quot;, section on 'Brentuximab'</a>.)</p><p>No renal toxicities have been reported with this agent; however, severe renal impairment increases the likelihood of severe adverse reactions and death in patients receiving brentuximab. The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3904f8dd-1aef-3490-e48f-bd55f32ed67f&amp;token=Ls1p7HX05n+R6CvlzDZzuL9MoxRvb7qms+9ab4jkbEMAvRueDwpGGEaxqyYlaAFSnH3A9W0mDNWbykfaxtMW2rpZn+pLEbLDWj5fuKXgJg0SPxzbCDE9WUmmiuh3t2QJ&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">United States prescribing information</a> for brentuximab and <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">Cancer Care Ontario guidelines</a> recommend avoidance of the drug in patients with creatinine clearance (CrCl) &lt;30 <span class=\"nowrap\">mL/min</span>.</p><p class=\"headingAnchor\" id=\"H1713298554\"><span class=\"h2\">Ibrutinib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ibrutinib-drug-information\" class=\"drug drug_general\">Ibrutinib</a> is an orally active inhibitor of Bruton tyrosine kinase, a mediator of the B cell receptor signaling pathway that inhibits malignant B cell survival; it is approved as a single agent for treatment of mantle cell lymphoma. (See <a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-mantle-cell-lymphoma#H15175889\" class=\"medical medical_review\">&quot;Treatment of relapsed or refractory mantle cell lymphoma&quot;, section on 'Ibrutinib'</a>.) </p><p>Serious and potentially fatal cases of acute kidney injury have occurred with <a href=\"topic.htm?path=ibrutinib-drug-information\" class=\"drug drug_general\">ibrutinib</a> therapy. In one report of 111 patients receiving ibrutinib for mantle cell lymphoma, acute kidney injury developed in three (2.7 percent) [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/127\" class=\"abstract_t\">127</a>]. Increases in serum creatinine levels of up to 1.5 times the upper limit of normal (ULN) and 1.5 to 3 times ULN have been reported in 67 and 9 percent of patients, respectively [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/128\" class=\"abstract_t\">128</a>]. The mechanism of this injury is unclear at this point, but tumor lysis syndrome might be contributory. (See <a href=\"topic.htm?path=tumor-lysis-syndrome-definition-pathogenesis-clinical-manifestations-etiology-and-risk-factors\" class=\"medical medical_review\">&quot;Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors&quot;</a>.)</p><p>Less than 1 percent of <a href=\"topic.htm?path=ibrutinib-drug-information\" class=\"drug drug_general\">ibrutinib</a> is excreted renally, and exposure is not altered in patients with mild to moderate renal dysfunction (CrCl &gt;25 <span class=\"nowrap\">mL/min)</span>. Data are not available for patients with worse renal function or those on dialysis.</p><p class=\"headingAnchor\" id=\"H446444158\"><span class=\"h2\">Olaparib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=olaparib-drug-information\" class=\"drug drug_general\">Olaparib</a> is a poly-adenosine diphosphate ribose polymerase (PARP) inhibitor that is approved for use in patients with <em>BRCA</em>-mutated ovarian cancer. It is extensively metabolized in the liver, and 44 percent of the drug is excreted in the urine. Increases in creatinine have been reported in 25 to 30 percent of patients treated with olaparib, but most are mild (only 2 percent are grade 3 (<a href=\"image.htm?imageKey=HEME%2F91253\" class=\"graphic graphic_table graphicRef91253 \">table 2</a>)) [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/129\" class=\"abstract_t\">129</a>]. The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e31a6a9-864f-4aba-8085-37ee1ddcd499&amp;token=6NBBsIG9F8rOT4ylbkE0yMQxKqZOHyd50yuFs8+BzqqbFtVGRfqhUm8Fmi0Wm9GGBy35jfPZt7dnSWPy1kHSRDJjx3H+6mpluHe1GioOWm0u0+tiJL4egsq36y68ZRaa&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">United States prescribing information</a> recommends a dose reduction for patients with moderate renal impairment (CrCl 31 to 50 <span class=\"nowrap\">mL/min)</span>. <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=114914\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a> also recommends a dose reduction for CrCl 31 to 50 <span class=\"nowrap\">mL/min</span> and suggests not using the drug with worse chronic kidney disease or end-stage renal disease.</p><p class=\"headingAnchor\" id=\"H3228479749\"><span class=\"h1\">CHECKPOINT INHIBITOR IMMUNOTHERAPY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Checkpoint inhibitors, immunomodulatory antibodies that are used to enhance the immune system, have substantially improved the prognosis for patients with advanced melanoma and are likely to significantly improve the treatment of advanced disease in a number of other malignancies. The primary targets for checkpoint inhibition include (see <a href=\"topic.htm?path=principles-of-cancer-immunotherapy\" class=\"medical medical_review\">&quot;Principles of cancer immunotherapy&quot;</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Programmed cell death 1 receptor (PD-1) and programmed cell death 1 ligand (PD-L1) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) </p><p/><p>Despite important clinical benefits, checkpoint inhibition is associated with a unique spectrum of side effects termed immune-related adverse events. Acute kidney injury is a rare complication of checkpoint inhibitor immunotherapy. The most common reported underlying pathology is acute tubulointerstitial nephritis, but immune complex glomerulonephritis and thrombotic microangiopathy have also been observed. This subject is discussed in detail elsewhere. (See <a href=\"topic.htm?path=toxicities-associated-with-checkpoint-inhibitor-immunotherapy#H645724\" class=\"medical medical_review\">&quot;Toxicities associated with checkpoint inhibitor immunotherapy&quot;, section on 'Kidney'</a>.)</p><p class=\"headingAnchor\" id=\"H233980680\"><span class=\"h1\">OTHER BIOLOGIC AGENTS</span></p><p class=\"headingAnchor\" id=\"H1747682368\"><span class=\"h2\">Interferons</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Recombinant interferon alfa (IFNa) can cause proteinuria, which can be massive; the histology is consistent with minimal-change nephropathy or focal segmental glomerulosclerosis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/130,131\" class=\"abstract_t\">130,131</a>]. Thrombotic microangiopathy is a rare complication seen mostly in patients with chronic myeloid leukemia treated with high doses of IFNa over long periods of time [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/132\" class=\"abstract_t\">132</a>]. (See <a href=\"topic.htm?path=epidemiology-classification-and-pathogenesis-of-focal-segmental-glomerulosclerosis#H1111547450\" class=\"medical medical_review\">&quot;Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis&quot;, section on 'Interferon'</a> and <a href=\"topic.htm?path=overview-of-kidney-disease-in-the-cancer-patient#H2590566064\" class=\"medical medical_review\">&quot;Overview of kidney disease in the cancer patient&quot;, section on 'Chemotherapy-associated glomerular disorders'</a>.)</p><p>Interferon gamma has been associated with acute tubular necrosis when used for the treatment of acute lymphoblastic leukemia [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/133\" class=\"abstract_t\">133</a>]. However, this agent is not currently used clinically for treatment of any neoplastic condition.</p><p class=\"headingAnchor\" id=\"H1664893907\"><span class=\"h2\">Interleukin-2</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=aldesleukin-drug-information\" class=\"drug drug_general\">Recombinant human interleukin-2</a> (IL-2) can induce a relatively severe capillary leak syndrome, leading to edema, plasma volume depletion, and a reversible fall in glomerular filtration rate (GFR) [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/134-136\" class=\"abstract_t\">134-136</a>]. For example, in one study of 199 consecutive patients, most patients experienced oliguria, hypotension, and weight gain, and 13 percent of cycles were discontinued because of a substantial rise in the plasma creatinine concentration (from 1.2 to 2.7 <span class=\"nowrap\">mg/dL</span> [106 to 238 <span class=\"nowrap\">micromol/L])</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/136\" class=\"abstract_t\">136</a>]. Poor renal function promptly reversed after cessation of therapy.</p><p>It has been proposed that plasma volume depletion is responsible for the development of acute renal failure. Although the clinical course and improvement in creatinine clearance (CrCl) and urine output following low-dose dopamine [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/137\" class=\"abstract_t\">137</a>] are compatible with this hypothesis, the observations that renal plasma flow is normal in affected patients [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/134\" class=\"abstract_t\">134</a>] and that the urinalysis may reveal red cells, white cells, granular casts, and modest proteinuria [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/135\" class=\"abstract_t\">135</a>] suggest that there may also be some direct renal injury.</p><p>Patients with normal renal function before treatment usually recover within the first week after discontinuing therapy. Patients with underlying renal dysfunction may take longer periods of time to recover from the renal failure.</p><p>Therapy for renal failure secondary to IL-2 treatment is supportive. It is directed at maintaining intravascular volume and stabilizing hemodynamic parameters, as well as avoiding other potential nephrotoxic agents. Preventive measures include a strict selection of patients who are candidates for IL-2 therapy. Older patients, patients with underlying renal failure, and patients taking nephrotoxic agents are at higher risk for complications such as capillary leak syndrome and prerenal azotemia.</p><p class=\"headingAnchor\" id=\"H1665666690\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Molecularly targeted anticancer agents can cause renal toxicity by a number of mechanisms. Several factors can potentiate renal dysfunction and contribute to nephrotoxicity, including intravascular volume depletion, the concomitant use of non-chemotherapeutic nephrotoxic drugs (eg, aminoglycoside antibiotics, nonsteroidal antiinflammatory drugs [NSAIDs]) or radiographic ionic contrast media in patients with or without preexisting renal dysfunction, tumor-related urinary tract obstruction, and intrinsic renal disease that is idiopathic, related to other comorbidities, or related to the cancer itself. These factors should be considered by the treating oncologist before initiating treatment in order to minimize the risk of excessive toxicity. (See <a href=\"topic.htm?path=chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents#H3\" class=\"medical medical_review\">&quot;Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents&quot;, section on 'Risk factors for nephrotoxicity'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For those drugs in which renal excretion is an important determinant of elimination of the intact drug or an active metabolite, renal impairment can alter excretion and increase systemic toxicity. Dose adjustment is often required. The most commonly used molecularly targeted agents for which dose modification may be needed in the setting of renal insufficiency are listed in the table (<a href=\"image.htm?imageKey=ONC%2F56245\" class=\"graphic graphic_table graphicRef56245 \">table 3</a>).</p><p/><p class=\"bulletIndent1\">Dose adjustment in this setting is typically based upon two factors: an estimation of glomerular filtration rate (GFR), which serves as an index of the number of functioning nephrons, and evaluation of clinical signs of drug toxicity (eg, neutropenia, thrombocytopenia). The available data in cancer patients suggest that all bedside formula for estimating GFR provide similar levels of concordance when used for the purpose of dosing renally excreted cancer drugs. (See <a href=\"topic.htm?path=chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents#H2\" class=\"medical medical_review\">&quot;Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents&quot;, section on 'Estimation of GFR for possible dose adjustment'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Minimizing nonrenal systemic toxicity in patients receiving molecularly targeted agents may be a particular problem in patients on chronic dialysis, especially when the details of drug elimination and metabolism are not fully known. For patients undergoing dialysis, two issues must be considered (see <a href=\"topic.htm?path=chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents#H263265423\" class=\"medical medical_review\">&quot;Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents&quot;, section on 'Drug handling in dialysis patients'</a>):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Since the kidneys are no longer functioning, dose reduction may be needed to avoid overexposure and drug toxicity.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Drug clearance by dialysis must be taken into account for appropriate timing of chemotherapy in patients treated with hemodialysis.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/1\" class=\"nounderline abstract_t\">Launay-Vacher V, Aapro M, De Castro G Jr, et al. Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN). Ann Oncol 2015; 26:1677.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/2\" class=\"nounderline abstract_t\">Jhaveri KD, Wanchoo R, Sakhiya V, et al. Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review. Kidney Int Rep 2017; 2:108.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/3\" class=\"nounderline abstract_t\">Jhaveri KD, Sakhiya V, Wanchoo R, et al. Renal effects of novel anticancer targeted therapies: a review of the Food and Drug Administration Adverse Event Reporting System. Kidney Int 2016; 90:706.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/4\" class=\"nounderline abstract_t\">Brosnan EM, Weickhardt AJ, Lu X, et al. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib. Cancer 2014; 120:664.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/5\" class=\"nounderline abstract_t\">Camidge DR, Brosnan EM, DeSilva C, et al. Crizotinib effects on creatinine and non-creatinine-based measures of glomerular filtration rate. J Thorac Oncol 2014; 9:1634.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/6\" class=\"nounderline abstract_t\">Lin YT, Wang YF, Yang JC, et al. Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer. J Thorac Oncol 2014; 9:1720.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/7\" class=\"nounderline abstract_t\">Klempner SJ, Aubin G, Dash A, Ou SH. Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatment. Oncologist 2014; 19:1008.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/8\" class=\"nounderline abstract_t\">Schnell P, Bartlett CH, Solomon BJ, et al. Complex renal cysts associated with crizotinib treatment. Cancer Med 2015; 4:887.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/9\" class=\"nounderline abstract_t\">Izzedine H, El-Fekih RK, Perazella MA. The renal effects of ALK inhibitors. Invest New Drugs 2016; 34:643.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/10\" class=\"nounderline abstract_t\">Johnson TR, Tan W, Goulet L, et al. Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects. Xenobiotica 2015; 45:45.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/11\" class=\"nounderline abstract_t\">Tan W, Yamazaki S, Johnson TR, et al. Effects of Renal Function on Crizotinib Pharmacokinetics: Dose Recommendations for Patients with ALK-Positive Non-Small Cell Lung Cancer. Clin Drug Investig 2017; 37:363.</a></li><li class=\"breakAll\">Cancer Drug information from Cancer Care Ontario http://cancercare.on.ca/cms/one.aspx?portalId=1377&amp;pageId=10760 (Accessed on September 14, 2017).</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/13\" class=\"nounderline abstract_t\">Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 2017; 390:29.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/14\" class=\"nounderline abstract_t\">Cortes JE, Gambacorti-Passerini C, Kim DW, et al. Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias. Clin Lymphoma Myeloma Leuk 2017; 17:684.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/15\" class=\"nounderline abstract_t\">Ozkurt S, Temiz G, Acikalin MF, Soydan M. Acute renal failure under dasatinib therapy. Ren Fail 2010; 32:147.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/16\" class=\"nounderline abstract_t\">Kaiafa G, Kakaletsis N, Savopoulos C, et al. Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report. J Clin Pharm Ther 2014; 39:102.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/17\" class=\"nounderline abstract_t\">Holstein SA, Stokes JB, Hohl RJ. Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia. Leuk Res 2009; 33:344.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/18\" class=\"nounderline abstract_t\">Martino S, Daguindau E, Ferrand C, et al. A successful renal transplantation for renal failure after dasatinib-induced thrombotic thrombocytopenic purpura in a patient with imatinib-resistant chronic myelogenous leukaemia on nilotinib. Leuk Res Rep 2013; 2:29.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/19\" class=\"nounderline abstract_t\">Uz B, Dolasik I. An unexpected and devastating adverse event of dasatinib: Rhabdomyolysis. Leuk Res Rep 2016; 5:1.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/20\" class=\"nounderline abstract_t\">Wallace E, Lyndon W, Chumley P, et al. Dasatinib-induced nephrotic-range proteinuria. Am J Kidney Dis 2013; 61:1026.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/21\" class=\"nounderline abstract_t\">Hirano T, Hashimoto M, Korogi Y, et al. Dasatinib-induced nephrotic syndrome. Leuk Lymphoma 2016; 57:726.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/22\" class=\"nounderline abstract_t\">Marcolino MS, Boersma E, Clementino NC, et al. Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. Ann Oncol 2011; 22:2073.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/23\" class=\"nounderline abstract_t\">Gafter-Gvili A, Ram R, Gafter U, et al. Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature. Leuk Res 2010; 34:123.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/24\" class=\"nounderline abstract_t\">Pou M, Saval N, Vera M, et al. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk Lymphoma 2003; 44:1239.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/25\" class=\"nounderline abstract_t\">Yilmaz M, Lahoti A, O'Brien S, et al. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer 2015; 121:3894.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/26\" class=\"nounderline abstract_t\">Yuzawa Y, Sato W, Masuda T, et al. Acute kidney injury presenting a feature of leukemic infiltration during therapy for chronic myelogenous leukemia. Intern Med 2010; 49:1139.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/27\" class=\"nounderline abstract_t\">Foringer JR, Verani RR, Tjia VM, et al. Acute renal failure secondary to imatinib mesylate treatment in prostate cancer. Ann Pharmacother 2005; 39:2136.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/28\" class=\"nounderline abstract_t\">Penel N, Blay JY, Adenis A. Imatinib as a possible cause of severe rhabdomyolysis. N Engl J Med 2008; 358:2746.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/29\" class=\"nounderline abstract_t\">Gordon JK, Magid SK, Maki RG, et al. Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec). Leuk Res 2010; 34:827.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/30\" class=\"nounderline abstract_t\">Barta VS, Uppal NN, Pullman JM, et al. Nephrotoxicity Corner | Acute tubular injury associated with imatinib (Gleevec): a case report and review of the literature. Journal of Onco-Nephrology 2017; 1:1.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/31\" class=\"nounderline abstract_t\">Vidal-Petiot E, Rea D, Serrano F, et al. Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 2016; 16:169.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/32\" class=\"nounderline abstract_t\">Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006; 354:2006.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/33\" class=\"nounderline abstract_t\">O'Sullivan S, Horne A, Wattie D, et al. Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. J Clin Endocrinol Metab 2009; 94:1131.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/34\" class=\"nounderline abstract_t\">Gibbons J, Egorin MJ, Ramanathan RK, et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 2008; 26:570.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/35\" class=\"nounderline abstract_t\">Pappas P, Karavasilis V, Briasoulis E, et al. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. Cancer Chemother Pharmacol 2005; 56:358.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/36\" class=\"nounderline abstract_t\">Ozdemir E, Koc Y, Kansu E. Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis. Am J Hematol 2006; 81:474.</a></li><li class=\"breakAll\">Renal pharmacotherapy: Dosage adjustment of medications eliminated by the kidneys., Golightly L, Teitelbaum I, Kizer TH, et al. (Eds), Springer, New York 2013.</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/38\" class=\"nounderline abstract_t\">Hino A, Yoshida H, Tada Y, et al. Changes from imatinib mesylate to second generation tyrosine kinase inhibitors improve renal impairment with imatinib mesylate in chronic myelogenous leukemia. Int J Hematol 2016; 104:605.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/39\" class=\"nounderline abstract_t\">Hurabielle C, Pillebout E, Stehl&eacute; T, et al. Mechanisms Underpinning Increased Plasma Creatinine Levels in Patients Receiving Vemurafenib for Advanced Melanoma. PLoS One 2016; 11:e0149873.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/40\" class=\"nounderline abstract_t\">Uthurriague C, Thellier S, Ribes D, et al. Vemurafenib significantly decreases glomerular filtration rate. J Eur Acad Dermatol Venereol 2014; 28:978.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/41\" class=\"nounderline abstract_t\">Regnier-Rosencher E, Lazareth H, Gressier L, et al. Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas. Br J Dermatol 2013; 169:934.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/42\" class=\"nounderline abstract_t\">Launay-Vacher V, Zimner-Rapuch S, Poulalhon N, et al. Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients. Cancer 2014; 120:2158.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/43\" class=\"nounderline abstract_t\">Jhaveri KD, Sakhiya V, Fishbane S. Nephrotoxicity of the BRAF Inhibitors Vemurafenib and Dabrafenib. JAMA Oncol 2015; 1:1133.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/44\" class=\"nounderline abstract_t\">Teuma C, Perier-Muzet M, Pelletier S, et al. New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma. Cancer Chemother Pharmacol 2016; 78:419.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/45\" class=\"nounderline abstract_t\">Denis D, Franck N, Fichel F, et al. Fanconi syndrome induced by vemurafenib: a new renal adverse event. JAMA Dermatol 2015; 151:453.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/46\" class=\"nounderline abstract_t\">Ouellet D, Gibiansky E, Leonowens C, et al. Population pharmacokinetics of dabrafenib, a BRAF inhibitor: effect of dose, time, covariates, and relationship with its metabolites. J Clin Pharmacol 2014; 54:696.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/47\" class=\"nounderline abstract_t\">Zhang W, Heinzmann D, Grippo JF. Clinical Pharmacokinetics of Vemurafenib. Clin Pharmacokinet 2017; 56:1033.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/48\" class=\"nounderline abstract_t\">Park JJ, Boddy AV, Liu X, et al. Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis. Pigment Cell Melanoma Res 2017; 30:68.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/49\" class=\"nounderline abstract_t\">Iddawela M, Crook S, George L, et al. Safety and efficacy of vemurafenib in end stage renal failure. BMC Cancer 2013; 13:581.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/50\" class=\"nounderline abstract_t\">Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367:1694.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/51\" class=\"nounderline abstract_t\">Maanaoui M, Saint-Jacques C, Gnemmi V, et al. Glomerulonephritis and granulomatous vasculitis in kidney as a complication of the use of BRAF and MEK inhibitors in the treatment of metastatic melanoma: A case report. Medicine (Baltimore) 2017; 96:e7196.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/52\" class=\"nounderline abstract_t\">Perico L, Mandal&agrave; M, Schieppati A, et al. BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome. Am J Kidney Dis 2017; 70:145.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/53\" class=\"nounderline abstract_t\">Abdel-Rahman O, ElHalawani H, Ahmed H. Risk of Selected Cardiovascular Toxicities in Patients With Cancer Treated With MEK Inhibitors: A Comparative Systematic Review and Meta-Analysis. J Glob Oncol 2015; 1:73.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/54\" class=\"nounderline abstract_t\">Ouellet D, Kassir N, Chiu J, et al. Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma. Cancer Chemother Pharmacol 2016; 77:807.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/55\" class=\"nounderline abstract_t\">Han K, Jin JY, Marchand M, et al. Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors. Cancer Chemother Pharmacol 2015; 76:917.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/56\" class=\"nounderline abstract_t\">Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005; 97:1221.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/57\" class=\"nounderline abstract_t\">Tejpar S, Piessevaux H, Claes K, et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 2007; 8:387.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/58\" class=\"nounderline abstract_t\">Groenestege WM, Th&eacute;bault S, van der Wijst J, et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest 2007; 117:2260.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/59\" class=\"nounderline abstract_t\">Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 2015; 16:763.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/60\" class=\"nounderline abstract_t\">Vermorken JB, St&ouml;hlmacher-Williams J, Davidenko I, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 2013; 14:697.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/61\" class=\"nounderline abstract_t\">Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/62\" class=\"nounderline abstract_t\">Cao Y, Liao C, Tan A, et al. Meta-analysis of incidence and risk of hypomagnesemia with cetuximab for advanced cancer. Chemotherapy 2010; 56:459.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/63\" class=\"nounderline abstract_t\">Vickers MM, Karapetis CS, Tu D, et al. Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. Ann Oncol 2013; 24:953.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/64\" class=\"nounderline abstract_t\">Vincenzi B, Santini D, Galluzzo S, et al. Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome. Clin Cancer Res 2008; 14:4219.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/65\" class=\"nounderline abstract_t\">Vincenzi B, Galluzzo S, Santini D, et al. Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. Ann Oncol 2011; 22:1141.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/66\" class=\"nounderline abstract_t\">Cao Y, Liu L, Liao C, et al. Meta-analysis of incidence and risk of hypokalemia with cetuximab-based therapy for advanced cancer. Cancer Chemother Pharmacol 2010; 66:37.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/67\" class=\"nounderline abstract_t\">Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 2004; 11:689.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/68\" class=\"nounderline abstract_t\">Sasaki K, Anderson E, Shankland SJ, Nicosia RF. Diffuse proliferative glomerulonephritis associated with cetuximab, an epidermal growth factor receptor inhibitor. Am J Kidney Dis 2013; 61:988.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/69\" class=\"nounderline abstract_t\">Ito C, Fujii H, Ogura M, et al. Cetuximab-induced nephrotic syndrome in a case of metastatic rectal cancer. J Oncol Pharm Pract 2013; 19:265.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/70\" class=\"nounderline abstract_t\">Berardi R, Santoni M, Rinaldi S, et al. Risk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical Trials. PLoS One 2016; 11:e0152079.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/71\" class=\"nounderline abstract_t\">Long A, Chigutsa E, Wallin J. Population Pharmacokinetics of Necitumumab in Cancer Patients. Clin Pharmacokinet 2017; 56:505.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/72\" class=\"nounderline abstract_t\">Krens LL, Baas JM, Verboom MC, et al. Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction. Cancer Chemother Pharmacol 2014; 73:1303.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/73\" class=\"nounderline abstract_t\">Dirks NL, Nolting A, Kovar A, Meibohm B. Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. J Clin Pharmacol 2008; 48:267.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/74\" class=\"nounderline abstract_t\">Thariat J, Azzopardi N, Peyrade F, et al. Cetuximab pharmacokinetics in end-stage kidney disease under hemodialysis. J Clin Oncol 2008; 26:4223.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/75\" class=\"nounderline abstract_t\">Cosmai L, Gallieni M, Porta C. Renal toxicity of anticancer agents targeting HER2 and EGFR. J Nephrol 2015; 28:647.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/76\" class=\"nounderline abstract_t\">Ma P, Yang BB, Wang YM, et al. Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors. J Clin Pharmacol 2009; 49:1142.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/77\" class=\"nounderline abstract_t\">Rossi A, Maione P, Del Gaizo F, et al. Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical cases. Lung Cancer 2005; 47:421.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/78\" class=\"nounderline abstract_t\">Miller AA, Murry DJ, Owzar K, et al. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol 2007; 25:3055.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/79\" class=\"nounderline abstract_t\">Togashi Y, Masago K, Fukudo M, et al. Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis. J Thorac Oncol 2010; 5:601.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/80\" class=\"nounderline abstract_t\">Fontana E, Pucci F, Ardizzoni A. Colorectal cancer patient on maintenance dialysis successfully treated with cetuximab. Anticancer Drugs 2014; 25:120.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/81\" class=\"nounderline abstract_t\">Kumasaka R, Nakamura N, Shirato K, et al. Side effects of therapy: case 1. Nephrotic syndrome associated with gefitinib therapy. J Clin Oncol 2004; 22:2504.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/82\" class=\"nounderline abstract_t\">Maruyama K, Chinda J, Kuroshima T, et al. Minimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib. Intern Med 2015; 54:823.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/83\" class=\"nounderline abstract_t\">Kaneko T, Shimizu A, Aoki M, Tsuruoka S. A case of gefitinib-associated membranous nephropathy in treatment for pulmonary adenocarcinoma. CEN Case Rep 2015; 4:31.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/84\" class=\"nounderline abstract_t\">Wiebe S, Schnell D, K&uuml;lzer R, et al. Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study. Eur J Drug Metab Pharmacokinet 2017; 42:461.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/85\" class=\"nounderline abstract_t\">Imai H, Kaira K, Naruse I, et al. Successful afatinib treatment of advanced non-small-cell lung cancer patients undergoing hemodialysis. Cancer Chemother Pharmacol 2017; 79:209.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/86\" class=\"nounderline abstract_t\">Bersanelli M, Tiseo M, Artioli F, et al. Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysis. Anticancer Res 2014; 34:3185.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/87\" class=\"nounderline abstract_t\">Gottschalk I, Berg C, Harbeck N, et al. Fetal Renal Insufficiency Following Trastuzumab Treatment for Breast Cancer in Pregnancy: Case Report und Review of the Current Literature. Breast Care (Basel) 2011; 6:475.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/88\" class=\"nounderline abstract_t\">Bader AA, Schlembach D, Tamussino KF, et al. Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy. Lancet Oncol 2007; 8:79.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/89\" class=\"nounderline abstract_t\">Watson WJ. Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios. Obstet Gynecol 2005; 105:642.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/90\" class=\"nounderline abstract_t\">Di&eacute;ras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 2017; 18:732.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/91\" class=\"nounderline abstract_t\">Boekhout AH, Beijnen JH, Schellens JH. Trastuzumab. Oncologist 2011; 16:800.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/92\" class=\"nounderline abstract_t\">Russo G, Cioffi G, Di Lenarda A, et al. Role of renal function on the development of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early breast cancer. Intern Emerg Med 2012; 7:439.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/93\" class=\"nounderline abstract_t\">Micallef RA, Barrett-Lee PJ, Donovan K, et al. Trastuzumab in patients on haemodialysis for renal failure. Clin Oncol (R Coll Radiol) 2007; 19:559.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/94\" class=\"nounderline abstract_t\">de Souza JA, Davis DW, Zhang Y, et al. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2012; 18:2336.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/95\" class=\"nounderline abstract_t\">Stallone G, Infante B, Pontrelli P, et al. Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm-associated proteins. Transplantation 2011; 91:997.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/96\" class=\"nounderline abstract_t\">Swaminathan S, Rosner MH. The podocyte under stress: AKT2 to the rescue. Am J Kidney Dis 2014; 63:555.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/97\" class=\"nounderline abstract_t\">Izzedine H, Boostandoot E, Spano JP, et al. Temsirolimus-induced glomerulopathy. Oncology 2009; 76:170.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/98\" class=\"nounderline abstract_t\">Izzedine H, Escudier B, Rouvier P, et al. Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven. Ann Oncol 2013; 24:2421.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/99\" class=\"nounderline abstract_t\">Lunardi G, Vannozzi MO, Armirotti A, et al. Temsirolimus in patients with renal cancer on hemodialysis. J Clin Oncol 2008; 26:5652.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/100\" class=\"nounderline abstract_t\">Gupta S, Parsa V, Heilbrun LK, et al. Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction. Anticancer Drugs 2011; 22:794.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/101\" class=\"nounderline abstract_t\">Garnier-Viougeat N, Rixe O, Paintaud G, et al. Pharmacokinetics of bevacizumab in haemodialysis. Nephrol Dial Transplant 2007; 22:975.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/102\" class=\"nounderline abstract_t\">Inauen R, Cathomas R, Boehm T, et al. Feasibility of using cetuximab and bevacizumab in a patient with colorectal cancer and terminal renal failure. Oncology 2007; 72:209.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/103\" class=\"nounderline abstract_t\">Khan G, Golshayan A, Elson P, et al. Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. Ann Oncol 2010; 21:1618.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/104\" class=\"nounderline abstract_t\">Gurevich F, Perazella MA. Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med 2009; 122:322.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/105\" class=\"nounderline abstract_t\">Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015; 16:619.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/106\" class=\"nounderline abstract_t\">Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381:303.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/107\" class=\"nounderline abstract_t\">Winn SK, Ellis S, Savage P, et al. Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect? Nephrol Dial Transplant 2009; 24:673.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/108\" class=\"nounderline abstract_t\">Khurana A. Allergic interstitial nephritis possibly related to sunitinib use. Am J Geriatr Pharmacother 2007; 5:341.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/109\" class=\"nounderline abstract_t\">Izzedine H, Brocheriou I, Rixe O, Deray G. Interstitial nephritis in a patient taking sorafenib. Nephrol Dial Transplant 2007; 22:2411.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/110\" class=\"nounderline abstract_t\">Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/111\" class=\"nounderline abstract_t\">Bellini E, Pia A, Brizzi MP, et al. Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism. Ann Oncol 2011; 22:988.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/112\" class=\"nounderline abstract_t\">Miller AA, Murry DJ, Owzar K, et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009; 27:1800.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/113\" class=\"nounderline abstract_t\">Kennoki T, Kondo T, Kimata N, et al. Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center. Jpn J Clin Oncol 2011; 41:647.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/114\" class=\"nounderline abstract_t\">Masini C, Sabbatini R, Porta C, et al. Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. BJU Int 2012; 110:692.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/115\" class=\"nounderline abstract_t\">Rey PM, Villavicencio H. Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience. Oncology 2008; 74:245.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/116\" class=\"nounderline abstract_t\">Czarnecka AM, Kawecki M, Lian F, et al. Feasibility, efficacy and safety of tyrosine kinase inhibitor treatment in hemodialyzed patients with renal cell cancer: 10 years of experience. Future Oncol 2015; 11:2267.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/117\" class=\"nounderline abstract_t\">Khosravan R, Toh M, Garrett M, et al. Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. J Clin Pharmacol 2010; 50:472.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/118\" class=\"nounderline abstract_t\">Izzedine H, Etienne-Grimaldi MC, Ren&eacute;e N, et al. Pharmacokinetics of sunitinib in hemodialysis. Ann Oncol 2009; 20:190.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/119\" class=\"nounderline abstract_t\">Josephs D, Hutson TE, Cowey CL, et al. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int 2011; 108:1279.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/120\" class=\"nounderline abstract_t\">Kim KH, Kim HY, Kim HR, et al. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency. Eur J Cancer 2014; 50:746.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/121\" class=\"nounderline abstract_t\">Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012; 30:134.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/122\" class=\"nounderline abstract_t\">Lee JS, Hirsh V, Park K, et al. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2012; 30:1114.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/123\" class=\"nounderline abstract_t\">Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012; 13:897.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/124\" class=\"nounderline abstract_t\">Chrisoulidou A, Mandanas S, Margaritidou E, et al. Treatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancer. Onco Targets Ther 2015; 8:2435.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/125\" class=\"nounderline abstract_t\">Shen H, Yang Z, Zhao W, et al. Assessment of vandetanib as an inhibitor of various human renal transporters: inhibition of multidrug and toxin extrusion as a possible mechanism leading to decreased cisplatin and creatinine clearance. Drug Metab Dispos 2013; 41:2095.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/126\" class=\"nounderline abstract_t\">Weil A, Martin P, Smith R, et al. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment. Clin Pharmacokinet 2010; 49:607.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/127\" class=\"nounderline abstract_t\">Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369:507.</a></li><li class=\"breakAll\">http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44#section-2.3 (Accessed on November 19, 2013).</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/129\" class=\"nounderline abstract_t\">Dean E, Middleton MR, Pwint T, et al. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br J Cancer 2012; 106:468.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/130\" class=\"nounderline abstract_t\">Selby P, Kohn J, Raymond J, et al. Nephrotic syndrome during treatment with interferon. Br Med J (Clin Res Ed) 1985; 290:1180.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/131\" class=\"nounderline abstract_t\">Markowitz GS, Nasr SH, Stokes MB, D'Agati VD. Treatment with IFN-{alpha}, -{beta}, or -{gamma} is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2010; 5:607.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/132\" class=\"nounderline abstract_t\">Zuber J, Martinez F, Droz D, et al. Alpha-interferon-associated thrombotic microangiopathy: a clinicopathologic study of 8 patients and review of the literature. Medicine (Baltimore) 2002; 81:321.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/133\" class=\"nounderline abstract_t\">Ault BH, Stapleton FB, Gaber L, et al. Acute renal failure during therapy with recombinant human gamma interferon. N Engl J Med 1988; 319:1397.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/134\" class=\"nounderline abstract_t\">Belldegrun A, Webb DE, Austin HA 3rd, et al. Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. Ann Intern Med 1987; 106:817.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/135\" class=\"nounderline abstract_t\">Mercatello A, Hadj-A&iuml;ssa A, N&eacute;grier S, et al. Acute renal failure with preserved renal plasma flow induced by cancer immunotherapy. Kidney Int 1991; 40:309.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/136\" class=\"nounderline abstract_t\">Guleria AS, Yang JC, Topalian SL, et al. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma. J Clin Oncol 1994; 12:2714.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents/abstract/137\" class=\"nounderline abstract_t\">Memoli B, De Nicola L, Libetta C, et al. Interleukin-2-induced renal dysfunction in cancer patients is reversed by low-dose dopamine infusion. Am J Kidney Dis 1995; 26:27.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 114914 Version 2.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H1665666690\"><span>SUMMARY</span></a></li><li><a href=\"#H3519476740\" id=\"outline-link-H3519476740\">INTRODUCTION</a></li><li><a href=\"#H1136913344\" id=\"outline-link-H1136913344\">ALK INHIBITORS</a><ul><li><a href=\"#H2194952856\" id=\"outline-link-H2194952856\">Crizotinib</a></li><li><a href=\"#H450284326\" id=\"outline-link-H450284326\">Other ALK inhibitors</a></li></ul></li><li><a href=\"#H1461924889\" id=\"outline-link-H1461924889\">BCL-2 INHIBITORS</a></li><li><a href=\"#H344532474\" id=\"outline-link-H344532474\">BCR-ABL1 AND KIT INHIBITORS</a><ul><li><a href=\"#H1044248852\" id=\"outline-link-H1044248852\">Bosutinib</a></li><li><a href=\"#H1767880974\" id=\"outline-link-H1767880974\">Dasatinib</a></li><li><a href=\"#H2722690434\" id=\"outline-link-H2722690434\">Imatinib</a></li><li><a href=\"#H116270820\" id=\"outline-link-H116270820\">Other agents</a></li></ul></li><li><a href=\"#H1514347373\" id=\"outline-link-H1514347373\">BRAF AND MEK INHIBITORS</a><ul><li><a href=\"#H1635907823\" id=\"outline-link-H1635907823\">Vemurafenib and dabrafenib</a></li><li><a href=\"#H3704499901\" id=\"outline-link-H3704499901\">Trametinib and cobimetinib</a></li></ul></li><li><a href=\"#H1535999760\" id=\"outline-link-H1535999760\">EGFR PATHWAY INHIBITORS</a><ul><li><a href=\"#H2372328215\" id=\"outline-link-H2372328215\">Anti-EGFR monoclonal antibodies</a></li><li><a href=\"#H1458609374\" id=\"outline-link-H1458609374\">EGFR tyrosine kinase inhibitors</a></li></ul></li><li><a href=\"#H2112553951\" id=\"outline-link-H2112553951\">HER2 INHIBITORS</a><ul><li><a href=\"#H1640769996\" id=\"outline-link-H1640769996\">Trastuzumab, ado-trastuzumab emtansine, and pertuzumab</a></li><li><a href=\"#H3979482629\" id=\"outline-link-H3979482629\">Lapatinib</a></li></ul></li><li><a href=\"#H993681564\" id=\"outline-link-H993681564\">MTOR INHIBITORS</a><ul><li><a href=\"#H2177291577\" id=\"outline-link-H2177291577\">Temsirolimus</a></li></ul></li><li><a href=\"#H1084264406\" id=\"outline-link-H1084264406\">VEGF PATHWAY INHIBITORS</a><ul><li><a href=\"#H3363773602\" id=\"outline-link-H3363773602\">Lenvatinib</a></li><li><a href=\"#H1973950167\" id=\"outline-link-H1973950167\">Regorafenib</a></li><li><a href=\"#H3855205339\" id=\"outline-link-H3855205339\">Sorafenib and sunitinib</a></li><li><a href=\"#H1794327396\" id=\"outline-link-H1794327396\">Vandetanib</a></li></ul></li><li><a href=\"#H213403592\" id=\"outline-link-H213403592\">OTHER TARGETED AGENTS</a><ul><li><a href=\"#H615177114\" id=\"outline-link-H615177114\">Brentuximab</a></li><li><a href=\"#H1713298554\" id=\"outline-link-H1713298554\">Ibrutinib</a></li><li><a href=\"#H446444158\" id=\"outline-link-H446444158\">Olaparib</a></li></ul></li><li><a href=\"#H3228479749\" id=\"outline-link-H3228479749\">CHECKPOINT INHIBITOR IMMUNOTHERAPY</a></li><li><a href=\"#H233980680\" id=\"outline-link-H233980680\">OTHER BIOLOGIC AGENTS</a><ul><li><a href=\"#H1747682368\" id=\"outline-link-H1747682368\">Interferons</a></li><li><a href=\"#H1664893907\" id=\"outline-link-H1664893907\">Interleukin-2</a></li></ul></li><li><a href=\"#H1665666690\" id=\"outline-link-H1665666690\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ONC/114914|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=HEME/91252\" class=\"graphic graphic_table\">- NCI CTCAE v5 electrolyte abnormalities</a></li><li><a href=\"image.htm?imageKey=HEME/91253\" class=\"graphic graphic_table\">- NCI CTCAE v5 acute kidney injury, creatinine increased</a></li><li><a href=\"image.htm?imageKey=ONC/56245\" class=\"graphic graphic_table\">- Chemo dose adj renal</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors\" class=\"medical medical_review\">Acneiform eruption secondary to epidermal growth factor receptor (EGFR) inhibitors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anaplastic-lymphoma-kinase-alk-fusion-oncogene-positive-non-small-cell-lung-cancer\" class=\"medical medical_review\">Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=antiangiogenic-and-molecularly-targeted-therapy-for-advanced-or-metastatic-clear-cell-renal-cell-carcinoma\" class=\"medical medical_review\">Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear-cell renal cell carcinoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=assessment-of-kidney-function\" class=\"medical medical_review\">Assessment of kidney function</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=biology-of-glomerular-podocytes\" class=\"medical medical_review\">Biology of glomerular podocytes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cardiotoxicity-of-trastuzumab-and-other-her2-targeted-agents\" class=\"medical medical_review\">Cardiotoxicity of trastuzumab and other HER2-targeted agents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=causes-of-hypokalemia-in-adults\" class=\"medical medical_review\">Causes of hypokalemia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents\" class=\"medical medical_review\">Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-magnesium-depletion\" class=\"medical medical_review\">Clinical manifestations of magnesium depletion</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-use-of-tyrosine-kinase-inhibitors-for-chronic-myeloid-leukemia\" class=\"medical medical_review\">Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-classification-and-pathogenesis-of-focal-segmental-glomerulosclerosis\" class=\"medical medical_review\">Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=gestational-breast-cancer-treatment\" class=\"medical medical_review\">Gestational breast cancer: Treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=kidney-disease-following-hematopoietic-cell-transplantation\" class=\"medical medical_review\">Kidney disease following hematopoietic cell transplantation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=molecularly-targeted-therapy-for-metastatic-melanoma\" class=\"medical medical_review\">Molecularly targeted therapy for metastatic melanoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-kidney-disease-in-the-cancer-patient\" class=\"medical medical_review\">Overview of kidney disease in the cancer patient</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathophysiology-and-etiology-of-the-syndrome-of-inappropriate-antidiuretic-hormone-secretion-siadh\" class=\"medical medical_review\">Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacology-of-mammalian-mechanistic-target-of-rapamycin-mtor-inhibitors\" class=\"medical medical_review\">Pharmacology of mammalian (mechanistic) target of rapamycin (mTOR) inhibitors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=principles-of-cancer-immunotherapy\" class=\"medical medical_review\">Principles of cancer immunotherapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=regulation-of-magnesium-balance\" class=\"medical medical_review\">Regulation of magnesium balance</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=secondary-factors-and-progression-of-chronic-kidney-disease\" class=\"medical medical_review\">Secondary factors and progression of chronic kidney disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=systemic-chemotherapy-for-metastatic-colorectal-cancer-completed-clinical-trials\" class=\"medical medical_review\">Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=systemic-therapy-for-advanced-non-small-cell-lung-cancer-with-an-activating-mutation-in-the-epidermal-growth-factor-receptor\" class=\"medical medical_review\">Systemic therapy for advanced non-small cell lung cancer with an activating mutation in the epidermal growth factor receptor</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=systemic-treatment-for-her2-positive-metastatic-breast-cancer\" class=\"medical medical_review\">Systemic treatment for HER2-positive metastatic breast cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=toxicities-associated-with-checkpoint-inhibitor-immunotherapy\" class=\"medical medical_review\">Toxicities associated with checkpoint inhibitor immunotherapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=toxicity-of-molecularly-targeted-antiangiogenic-agents-cardiovascular-effects\" class=\"medical medical_review\">Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=toxicity-of-molecularly-targeted-antiangiogenic-agents-non-cardiovascular-effects\" class=\"medical medical_review\">Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-chronic-myeloid-leukemia-in-chronic-phase-after-failure-of-initial-therapy\" class=\"medical medical_review\">Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-chronic-lymphocytic-leukemia\" class=\"medical medical_review\">Treatment of relapsed or refractory chronic lymphocytic leukemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-mantle-cell-lymphoma\" class=\"medical medical_review\">Treatment of relapsed or refractory mantle cell lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\" class=\"medical medical_review\">Treatment of relapsed or refractory peripheral T cell lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tumor-lysis-syndrome-definition-pathogenesis-clinical-manifestations-etiology-and-risk-factors\" class=\"medical medical_review\">Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tyrosine-kinase-inhibitor-therapy-for-advanced-gastrointestinal-stromal-tumors\" class=\"medical medical_review\">Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors</a></li></ul></div></div>","javascript":null}